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**Background :**Von Willebrand Factor (VWF) is crucial for arterial thrombosis and its plasma levels are increased in acute coronary syndromes (ACS). Effects of conventional platelet inhibitors are compromised by elevated VWF under high shear rates. BT200 is a third generation aptamer that binds and inhibits the A1 domain of human VWF.

**Aims :**

i\) To study whether VWF is a predictor of mortality in ACS patients under potent P2Y12 blocker therapy and

ii\) To examine the effects of a VWF inhibiting aptamer BT200 and its concentrations required to inhibit VWF in plasma samples of patients with ACS.

**Methods :**VWF activity was measured in 321 patients with ACS, and concentration‐ effect curves of BT200 were established in plasma pools containing different VWF concentrations.

**Results :**Median VWF activity in our population was 170% (IQR%CI: 85--255) and 44% of patients had high (\>180%) VWF activity. Plasma levels of VWF activity predicted short (HR = 2.50; 95% CI = 1.11--5.59) and long‐term (HR = 2.65; 95% CI = 1.14--6.15) mortality despite treatment with potent platelet inhibitors (dual antiplatelet therapy with aspirin and prasugrel or ticagrelor). Consistent with previous findings, age was an independent discriminator of VWF activity. Concentrations of BT200 ranging from 0.42 to 2.13 μg/mL inhibited VWF activity to \< 20% of normal in the different plasma pools (*P* \< 0.0001) and higher concentrations of BT200 were needed in the presence of increasing VWF activity.

**Conclusions :**VWF is a predictor of all‐cause mortality in ACS patients under contemporary potent antiplatelet therapy. BT200 potently inhibited VWF activity in a target concentrations dependent manner.

OC 01.2 {#rth212401-sec-0004}
=======

Low‐grade Endotoxaemia Enhances Artery Thrombus Growth via Toll‐like Receptor 4: Implication for Myocardial Infarction {#rth212401-sec-0005}
----------------------------------------------------------------------------------------------------------------------

**[C. Nocella]{.ul}^1^, R. Carnevale^2^, S. Sciarretta^2^, V. Cammisotto^2^, V. Valenti^2^, C. Calvieri^2^, G. Frati^2^, G. D\'Amati^2^, R. Cangemi^2^, A. Arrivi^3^, M. Dominici^3^, E. Mangeri^2^, C. Gaudio^2^, G. Tanzilli^2^, F. Violi^2^**

^1^Sapienza University of Rome, Department of Clinical, Internal Medicine, Anesthesiology and Cardiovascular Sciences, Rome, Italy^2^Sapienza University of Rome, Rome, Italy^3^Santa Maria Hospital, Terni, Italy

**Background :**Escherichia Coli (EC) lipopolysaccharide, which is a component of gut microbiota, is detectable in human circulation at concentrations potentially eliciting platelet aggregation; however, its role in thrombosis is still unclear.

**Aims :**To evaluate if low‐grade endotoxemia by EC in patients with coronary heart disease may favour thrombus growth at site of coronary unstable plaques.

**Methods :**We measured serum lipopolysaccharide (LPS) concentration, soluble P‐selectin (sP‐selectin), a marker of platelet activation, and zonulin, a marker of gut permeability, in peripheral circulation, coronary thrombi, and intracoronary blood of patients with ST‐elevation myocardial infarction (STEMI, n = 50) and stable angina (SA) (n = 50), respectively, and in controls (n = 50).

**Results :**Coronary thrombi from STEMI showed higher concentrations of LPS, sP‐selectin vs. intracoronary blood of SA and peripheral blood of controls (*P* \< 0.001). Zonulin was higher in STEMI compared to the other two groups \[4.57 (3.34--5.22); 2.56 (0.41--4.36); 1.95 (1.22--2.65) ng/mL; *P* \< 0.001\] and correlated with LPS (Rs = 0.585; *P* \< 0.001). Escherichia coli DNA was positive in 34% of STEMI vs. 12% of SA and 4% of controls (*P* \< 0.001). In a subgroup of 12 STEMI, immunohistochemical analysis of coronary thrombi showed positivity for leucocyte Toll‐like receptor 4 (TLR4), cathepsin G, and LPS from E. coli in 100%, 80%, and 25% of samples, respectively. E. coli‐LPS injected in mice to reach LPS concentrations like those detected in coronary thrombi was associated with enhanced artery thrombosis and platelet activation, an effect blunted by TLR4 inhibitor co‐administration. In vitro study demonstrated that LPS from E. coli enhanced platelet aggregation via TLR4‐mediated leucocyte cathepsin G activation.

**Conclusions :**ST‐elevation myocardial infarction patients disclose an enhanced gut permeability that results in LPS translocation in human circulation and eventually thrombus growth at site of artery lesion via leucocyte‐platelet interaction.
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**Background :**Atherosclerosis is a progressive inflammatory vascular disorder, complicated by plaque rupture causing atherothrombosis. Animal studies indicate that thrombin and factor Xa (FXa) promote atherosclerosis through activation of protease activated receptors. We showed that inhibition of FXa by rivaroxaban not only reduced atherogenesis, but also promoted regression of plaques in ApoE^−/−^ mice.

**Aims :**By analyzing aortic bulk RNAseq data from ApoE^−/−^ mice, we aim to find genes that could explain the beneficial effects of FXa inhibition on atherosclerosis.

**Methods :**Female ApoE^−/−^ mice (age 8--9 weeks) on western type diet (WTD) or WTD + 1.2 mg/g rivaroxaban for 14 weeks. In a second arm, mice on WTD for 14 weeks, followed by WTD ± 1.2 mg/g rivaroxaban for 6 weeks (total 20 weeks). For the purpose of this abstract we will focus only on the 14 weeks group. RNA was isolated from aortic arches, sequenced with Illumina (30 mil. reads per sample n = 6 per group), aligned to the transcriptome and analyzed with DEseq2. Differentially expressed genes with p‐adjusted \< 0.1 were considered to be significant. For gene enrichment analysis differentially expressed genes with ≥ 1.0‐fold (log2 scale) and *P*adj \< 0.25 were used.

**Results :**190 of 19704 genes were significantly differentially expressed: 90 were down‐ and 100 upregulated in the rivaroxaban‐treated group. Top downregulated genes included *Adamts1*,*Ighg2b* and *Hspa1a*, whereas top upregulated genes included *ADTRP*,*Ptgds*, and *Angptl8*. Top enriched pathways included KEGG pathways of complement and coagulation (Table 1 and Fig 1). Most enriched reactome pathways included those that are involved in IGF transport and uptake, regulation of TLR by endogenous ligand and platelet degranulation (Table 1).

**Conclusions :**Direct inhibition of FXa by rivaroxaban attenuated atherosclerosis. RNA‐seq and enrichment analysis showed that inhibition of FXa has a significant effect on gene expression. Modulation of multiple biological pathways related to atherosclerosis highlight the multi‐faceted role of coagulation Factor Xa.

**Table 1** Enrichment AnalysisKEGG Pathways Term DescriptionObserved Gene CountBackground Gene Count*P* ValueMatching Proteins in NetworkComplement and coagulation cascade3880.0204*Fga, Kng1, SerpinF2*Reactome Pathways Term DescriptionObserved Gene CountBackground Gene Count*P* ValueMatching Proteins in NetworkRegulation of insulin‐like growth factor (IGF) transport and uptake by IGF binding protein41290.0045*Apob, Chgb, Fga, Kng1*Post‐translational protein phosphorylation41140.0045*Apob, Chgb, Fga, Kng1*Regulation of TLR by endogenous ligand2130.0094*Apob, Fga*Platelet degranulation31210.0292*Fga, Kng1, Serpinf2*Formation of Fibrin Clot (clotting cascade)2340.0292*Fga, Kng1*G alpha (i) signaling events43380.0356*Apob, Ccr4, Kng1, Rgs9 bp*

**Figure 1** Protein‐Protein Interaction using 37 differentially expressed genes
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**Background :**Active shuttling of Ca^2+^ is required for inflammatory signal progression. During muscle cell activation this Ca^2+^ import is supported by an efflux of Na^+^. Whether this system is also required during inflammation is so far unknown.

**Aims :**To determine if Na^+^ content of a cell modulates its inflammatory response in vitro and in vivo using an approved compound that reduces cellular Na^+^ intake termed Ranolazine.

**Methods :**Antiinflammatory properties of ranolazine were tested in a LDL‐R^−/−^ atherosclerotic mouse model and in a patient cohort involving 47 patients randomized to either ranolazine or control treatment for 3 months. The mode of action of ranolazine was determined in an endothelial cell culture model using human umbilical vein endothelial cells.

**Results :**Atherosclerotic plaque analysis in an atherosclerotic mouse model on a high fat diet demonstrated reduced atherosclerotic plaque burden, increased plaque stability and reduced macrophage infiltration in mice treated with ranolazine. Human patient data supported this finding, as plasma levels of IL‐6 and hs‐CRP were significantly reduced after ranolazine treatement whereas the control treatment group did not show changes in those inflammatory markers. Mechanistically, we suggest that ranolazine reduces the Na^+^ content of cells leading to an abrogation of inflammation induced Ca^2+^ entry resulting in a massive reduction of inflammation induced adhesion molecules (ICAM, VCAM, and E‐SELECTIN) and soluble cytokines (IL‐6 and IL‐8) in endothelial cells. This reduction of inflammation is linked to reduced activation of the NF‐κB pathway. RNAi mediated knockdown of SLC8A1, a sodium calcium exchanger, phenocopied the results obtained with ranolazine.

**Conclusions :**The presented findings suggest anti‐inflammatory effects of ranolazine in a mouse model of atherosclerosis, in human patients and in in vitro experiments. This might be due to a modulation of intracellular Na^+^ levels resulting in a decreased capacity to mount a full response to inflammation.
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**Background :**Atherosclerosis and its cardiovascular and cerebrovascular complications are the most common causes of death, according to the latest data released by the WHO. And platelets take part in all stages of atherogenesis and especially in thrombus formation at the ruptured plaques. Therefore, to explore an effective prevention and novel therapeutic approaches are crucial and urgent.

**Aims :**We wanted to elucidate the impact of platelet specific TGF‐β1‐deficiency on atherogenesis and chronic CD4^+^ T cell immunity, using a no‐germline genetic engineering atherosclerosis mouse model.

**Methods :**We established a murine strain with platelet‐selective TGF‐β1‐deficiency "PF4‐Cre + ‐TGF‐β1^f/f^". And then we established atherosclerotic mouse model via combining PCSK9‐encoding rAAV8 vectors by tail vein injection and with a cholate‐free Western‐type high‐fat diet. The time points were 10w and 15w after high‐fat diet. We have measured many indicators, such as 1) Weight and heart weight; 2) Plasma TGF‐β1; 3) Twenty two whole blood indicators including neutrophil, platelets, and etc.; 4) Ten correlated lipid level indicators including Cho, LDL‐C, TG, and etc.; 5) Aorta en face staining and atherosclerotic lesions in the aortic root (Oil Red O staining); 6) Flow cytometry of spleen and lymph nodes including Th1, Treg, etc.; 7) PCR of spleens, and aortas; 8) IHC staining like CD4; and etc.

**Results :**We found that neutrophil, platelets, and lipid level of the experimental group increased significantly; the results of Oil Red O staining and flow cytometry analysis, and etc. together showed that atherosclerosis was aggravated in the experimental group obviously.

**Conclusions :**Platelets are an active and multifaceted engager in vascular inflammatory microenvironment. Platelet‐derived TGF‐β1 has an important protective effect for angiocarpy. True impacts of platelets on vascular microenvironment depend on the total readout of multiply factors. Future work is needed for the intervention strategy of platelet inflammatory activities.
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**Background :**FXIIIa crosslinks fibrin α‐ and γ‐chains, increasing resistance to mechanical strain. The role of thrombus mechanical properties in thromboembolism *in‐vivo* is poorly understood. In addition, current thromboembolism models are limited as they are based on systemic clotting or injection of exogenous thrombi.

**Aims :**To develop a genetically‐modified mouse, with reduced clot elasticity due to mutations in the fibrin γ‐γ crosslinking sites, and to investigate the role of clot elasticity in thromboembolism using newly developed protocols.

**Methods :**FGG3X mice were generated by mutating the conserved fibrinogen γ‐chain crosslinking residues (γQ423N/Q424N/K431R). Clot formation was analysed *ex‐vivo* by ROTEM and *in‐vivo* by intravital microscopy using a FeCl3 femoral vein injury model. Additionally, pulmonary embolism was investigated live by Xtreme optical imaging, and after one hour by light‐sheet microscopy, following FeCl3 injury to the inferior *vena cava* of mice injected with AlexaFluor^647^‐fibrinogen.

**Results :**FGG3X mice were phenotypically (growth, haematological parameters) similar to WT (C57BL/6), but were unable to form γ‐γ crosslinks. ROTEM clotting and lysis times were similar, however maximum clot firmness was significantly lower in FGG3X mice compared to WT, showing a reduction in clot elastic modulus. Intravital microscopy showed FGG3X mice exhibited significantly increased breakdown events during thrombus formation, compared to WT. Furthermore, Xtreme imaging showed that embolisation to the lungs was significantly higher in FGG3X mice compared to WT, at 0.5, 1, 2, 4, 24 hours post‐injury of the *vena cava*. Light‐sheet microscopy of the lungs 1 hour post‐injury showed a significant increase in emboli count and volume for FGG3X mice, compared to WT.

**Conclusions :**Our data show that γ‐γ crosslinking plays a key role in clot stability during thrombosis *in‐vivo*, and protects against pulmonary embolism. This points to important mechanistic targets for the prevention of thromboembolism through selective modulation of fibrin crosslinking to reduce thrombus burden, while maintaining clot stability.
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**Background :**Plasma fibrinogen concentration correlates with cardiovascular disease (CVD) event risk, but a causative role for fibrinogen has not been established, and it is unclear if lowering fibrinogen levels could be beneficial for CVD. A small molecule modulator of fibrinogen production could be used to investigate this.

**Aims :**We aimed to identify chemical entities capable of changing fibrinogen production and test their impact on experimental thrombosis.

**Methods :**1280 compounds were screened for their ability to alter fibrinogen production in hepatocyte‐derived HepG2 cells. The screen was performed three times and lead compounds tested for dose‐responsiveness and efficacy prior to validation in human HuH7 and murine AML12 cells. A panel of compounds were assessed for fibrinogen modulation and effects on laser‐induced venous thrombosis assays in zebrafish larvae. Gene expression, proteomics, and morpholino‐based mRNA knockdowns were used to investigate mechanisms‐of‐action.

**Results :**Our chemical screen identified anthralin and *all‐trans* retinoic acid (RA) as fibrinogen‐lowering and fibrinogen‐increasing moieties, respectively. In zebrafish larvae, anthralin prolonged laser‐induced venous‐occlusion times and reduced thrombocyte accumulation at injury sites. RA had the opposite effects. Anthralin had little effect on fibrinogen mRNA in zebrafish larvae but, using a proteomic scan of anthralin‐treated cells and zebrafish, we detected reduced representation of proteins with secretory signal peptides, suggesting a mechanism whereby anthralin affects proteins via the canonical secretory pathway. Treatment of cultured cells or zebrafish larvae with RA increased steady‐state fibrinogen mRNA. Using a morpholino oligonucleotide to deplete zebrafish fibrinogen mRNA, we correlated the shortening of venous thrombosis times with RA and fibrinogen protein levels.

**Conclusions :**We identified anthralin as a fibrinogen‐lowering small molecule and are now testing its effects on fibrinogen levels and hemostasis in mice. Anthralin, or an optimized derivative with improved selectivity, could be used to assess the protective effect of lowering plasma fibrinogen on cardiovascular disease‐related event risk.
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**Background :**Histones released from activated or damaged and dying cells are associated with poor outcome in sepsis and cardiovascular and cerebrovascular disease. As major components of neutrophil extracellular traps (NETs), histones together with DNA are causally implicated in arterial, venous, and microvascular thrombosis by promoting coagulation and enhancing clot stability. Their presence in patient thrombi is a potential obstacle to effective thrombolytic therapy.

**Aims :**To determine the mechanisms behind the enhanced lytic stability of clots containing histones.

**Methods :**Fibrinolytic assays with purified components, plasma and whole blood (ROTEM^®^) were supported by kinetic and biochemical studies with FXIIIa inhibitors, recombinant proteins, and deficient plasmas.

**Results :**Although histones stimulated plasminogen activation by tPA in solution, they delayed fibrinolysis by competitively inhibiting plasmin to protect fibrin from degradation. Histones were noncovalently and covalently associated with fibrin isolated from clotted blood but not from FXIIIa‐deficient plasma (Figure 1). Covalent interactions were abolished by FXIIIa inhibitors and restored by purified FXIII. All histones subtypes (H1, H2A, H2B, H3, and H4), expressed as recombinant his‐tagged proteins, were directly crosslinked to fibrin by FXIIIa. The antifibrinolytic and clot‐strengthening effects of histones were largely negated by FXIIIa inhibition (Figure 2). Therapeutic doses of low molecular weight heparin bound histones and prevented covalent but not noncovalent histone‐fibrin interactions and neutralised their antifibrinolytic potency.

**Conclusions :**DNase is proposed to dismantle NETs and improve thrombolysis. However, histones remain and alter the structure and composition of fibrin to promote clot stability and fibrinolytic resistance. FXIIIa is responsible for mediating these effects by crosslinking histones to fibrin, where they inhibit plasmin. Our findings provide a rationale for targeting the FXIII‐histone‐fibrin axis with FXIIIa inhibitors and heparinoids to improve thrombolysis and prevent thrombosis. They also emphasise that thrombi are complex mixtures of cells and cell‐derived factors, the electrostatic and covalent crosslinking of which are under‐explored factors in clot stability.

**Figure 1**

**Figure 2**
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**Background :**Citrullination, the conversion of peptidyl‐arginine into peptidyl‐citrulline is catalyzed by PAD (peptidyl‐arginyl‐deiminase) enzymes. Fibrin, the main scaffold of thrombi is susceptible to PAD2/4 released during NETosis by neutrophils, which are abundant in pathological thrombi. However, no study has investigated the presence and significance of citrullinated fibrin(ogen) in thrombi formed in vivo.

**Aims :**We hypothesized that citrullinated fibrin(ogen) is present in venous thrombi, altering the structural, mechanical and fibrinolytic properties of the clots.

**Methods :**Thrombi were induced in a mouse inferior vena cava stenosis model. Citrullinated fibrin(ogen) was detected with a specifically designed western blot‐based protocol. In vitro citrullination of fibrinogen was performed with purified PAD4. The structure and biomechanical properties of fibrin formed from citrullinated fibrinogen were examined with a broad range of methods (scanning‐electron/laser‐scanning/atomic‐force microscopy‐SEM/LSM/AFM, rheometry, turbidimetry, permeability measurements, small‐angle X‐ray scattering‐SAXS, nano‐thromboelastography).

**Results :**Citrullinated fibrinogen was abundant in thrombi formed 1--48 hour post ligation, but not in concurrent plasma samples (Fig. 1). In pure fibrin clots, SEM confirmed a 34% decrease in median fiber diameters after extensive citrullination, while the width/length ratios and fractal geometry of fibers remained preserved according to AFM and SAXS. LSM showed increased fiber density (Fig. 2A), and accordingly clot permeability declined by \> 50% even after milder citrullination. Mechanical stability of citrullinated clots was compromised as evidenced by a 50% decrease in maximal cantilever pulling force in nano‐thromboelastography (Fig. 2B) and a 30% decrease in the critical shear stress needed to disassemble clots in rheometry. Both plasmin‐ and tPA‐mediated fibrinolysis were hindered in pure fibrin and plasma clots containing citrullinated fibrinogen.

**Conclusions :**For the first time, we provide evidence for the presence of citrullinated fibrin(ogen) in venous thrombi. Furthermore, we show that citrullination contributes to a clot structure that is lysis‐resistant because of higher compactness and lower porosity, but mechanically vulnerable and consequently more prone to embolization.

**Figure 1** Citrullinated fibrin(ogen) is abundant in murine thrombi, but not in plasma

**Figure 2** Structure and biomechanical properties of citrullinated fibrin

OC 02.5 {#rth212401-sec-0021}
=======

Low α2‐plasmin Inhibitor Antigen Levels on Admission Predict Unfavorable Outcomes in Acute Ischemic Stroke Patients Treated with Intravenous Thrombolysis {#rth212401-sec-0022}
---------------------------------------------------------------------------------------------------------------------------------------------------------

**R. Orbán‐Kálmándi^1^, B. Baráth^1^, F. Sarkady^1^, E. Székely^1^, I. Szegedi^2^, K.R. Czuriga‐Kovács^2^, I. Fekete^2^, K. Fekete^2^, É. Katona^1^, L. Csiba^2^, [Z. Bagoly]{.ul}^1,3^**

^1^University of Debrecen, Faculty of Medicine, Division of Clinical Laboratory Sciences, Debrecen, Hungary^2^University of Debrecen, Faculty of Medicine, Department of Neurology, Debrecen, Hungary^3^MTA‐DE Cerebrovascular and Neurodegenerative Research Group, Debrecen, Hungary

**Background :**Intravenous thrombolysis by recombinant tissue plasminogen activator (rt‐PA) fails to achieve recanalization in a large subset of acute ischemic stroke (AIS) patients, while in approximately 6--8% of cases intracerebral hemorrhage (ICH) occurs.

**Aims :**Here we aimed to investigate α2‐plasmin inhibitor (α2‐PI) levels during thrombolysis and to find out whether they predict therapy outcomes in AIS patients.

**Methods :**In this prospective, observational study, blood samples of 418 AIS patients, all undergoing intravenous thrombolysis by rtPA within 4.5 hours of their symptom onset, were taken before and 24 hours after thrombolysis. In a subset of patients (n = 131), blood was also obtained immediately post‐lysis. α2‐PI activity and antigen levels were measured by chromogenic assay and an in‐house ELISA detecting all forms of α2‐PI, respectively. Stroke severity was determined by NIHSS on admission, day 1 and 7. Therapy‐associated ICH was classified according to ECASSII. Long‐term outcomes were defined at 3 months post‐event by the modified Rankin Scale (mRS). All patients or relatives provided informed consent.

**Results :**Median α2‐PI activity and antigen levels showed a significant drop immediately post‐lysis and increased to subnormal levels at 24 hours post‐event. α2‐PI levels on admission showed a significant negative step‐wise association with stroke severity. Patients with favorable long‐term outcomes (mRS 0--1) had significantly higher on admission α2‐PI antigen levels (median:61.4 \[IQR:55.5--70.5\] mg/L) as compared to patients with poor outcomes (mRS 2--5: median:58.9 \[IQR:52.8--66.7\] and mRS 6: median:56.4 \[IQR:50.9--61.0\] mg/L, *P* = 0.009). A multiple logistic regression model revealed that an α2‐PI antigen level in the lower quartile before thrombolysis is an independent predictor of poor outcome (mRS \> 2) at 3 months after the event (OR:1.72; 95% CI:1.02--2.95, *P* = 0.044). In patients with therapy‐related ICH (n = 32), admission α2‐PI antigen levels were significantly lower as compared to those without hemorrhagic complications.

**Conclusions :**A low α2‐PI antigen level on admission is an independent predictor of unfavorable long‐term outcomes in AIS patients undergoing thrombolysis.
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**Background :**High‐throughput quantitative immunomics data is growing rapidly. Next generation sequencing (NGS) analysis of combinatorial phage display libraries, Mimotope Variation Analysis (MVA) has the potential to characterize the immune response profile of patients at the *omic* level.

**Aims :**To dissect the inhibitory response against early replacement therapy (first 50 EDs) in previously untreated patients (PUPs) with severe haemophilia A receiving either plasma‐derived (pdFVIII) or recombinant factor VIII (rFVIII).

**Methods :**MVA was performed on plasma samples collected before (T0) and after (EOS) FVIII infusion collected from 80 PUPs within the SIPPET study cohort. EOS samples were also analyzed in a competition MVA (Block) experiment resulting in therapy‐specific immune response depletion.

To address dataset size and complexity (sequence diversity = 34\*10^6^) a custom denoising pipeline was developed by exploiting the Hammock software. Differential analysis of the resulting mimotopes was performed by Wilcoxon test. Overall cluster abundance was studied by PERMANOVA.

**Results :**Explorative correlation analysis showed that the relationship between EOS and Block samples was strongly reduced in patients treated with pdFVIII than in patients treated with rFVIII (*P* \< 0.001) suggesting a broader immune response toward the plasma‐derived therapy.

In patients treated with rFVIII, differential analysis revealed 23 clusters associated with inhibitor development. Importantly, one was significant also at T0 (AUC = 0.8, adj *P* = 0.01). In patients treated with pdFVIII, we found 203 clusters associated with inhibitor development. The abundance of these clusters in both groups was different in T0 compared with EOS (*P* = 0.001), supporting their mimicry of therapy‐specific antigens.

**Conclusions :**Our results show a differential immune response in patients treated with pdFVIII or rFVIII during the first 50EDs. Even if further analyses are required to understand their biological meaning, we found different therapy‐specific antigens associated to inhibitor development and one of those showed also a prognostic value.
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**Background :**PUPs A‐LONG is the first study evaluating an extended half‐life (EHL), recombinant factor VIII Fc fusion protein (rFVIIIFc), in previously untreated patients (PUPs) with haemophilia A.

**Aims :**To evaluate safety, including inhibitor development, and efficacy of rFVIIIFc in PUPs.

**Methods :**This open‐label, multicentre, Phase 3 study (NCT02234323) enrolled male PUPs aged ˂6 years with haemophilia A (˂1 IU/dL endogenous FVIII) to receive rFVIIIFc. Primary endpoint was inhibitor development (incidence rate=number of patients with inhibitor/number of patients reaching ≥ 10 exposure days (ED) milestone or with inhibitor). A secondary endpoint was annualized bleeding rate (ABR).

**Results :**Of 103 patients receiving ≥ 1 dose; 80 (77.7%) were ˂1‐year old; 20 (19.4%) had a family history of inhibitors, and 82 (79.6%) had a high‐risk haemophilia genotype. Eighty‐one patients started on episodic treatment; of these, 69 switched to prophylaxis. Twenty patients started on prophylaxis and 2 were not assigned a regimen. Eighty‐seven (84.5%) patients completed the study. Eighty‐seven (84.5%), 85 (82.5%), and 81 (78.6%), patients had ≥ 10, ≥20, ≥50 EDs to rFVIIIFc, respectively. Total and high‐titre (≥5.00 BU/mL) inhibitor rate was 31.1% (28/90) and 15.6% (14/90), respectively, for patients with ≥ 10 EDs (3 inhibitor patients with ˂10 EDs included). Median time to inhibitor development was 9 EDs (range: 1--53). rFVIIIFc dosing and efficacy data in Table 1. Twenty‐eight (27.2%) had rFVIIIFc treatment‐related serious adverse events (TESAEs); FVIII inhibition, n = 28; soft tissue haemorrhage, n = 1; deep vein/CVAD‐associated thromboses, n = 2). There was 1 non‐treatment‐related death due to intracranial haemorrhage (onset during screening period prior to first rFVIIIFc dose).

**Conclusions :**This was the first prospective study of an EHL rFVIIIFc treatment for PUPs with severe haemophilia A. Overall inhibitor development was in the range that can be expected, although high‐titre incidence was lower than that reported in the literature. The data demonstrate that rFVIIIFc was well tolerated and effective in this paediatric patient population.

**Table 1** Annualized bleeding rate, number of injections required for resolution of a bleeding episode and response to treatmentTreatmentEpisodic (n = 81\*)Prophylactic (n = 89\*)rFVIIIFc dose (n = 88)rFVIIIFc dose (n = 88)N/A101.44 (62.98, 138.68)Average dosing interval, median (IQR), daysN/A3.87 (3.28--4.74)Number of weeks on rFVIIIFcMedian, (range)23.57 (0.4--107.8)43.97 (0--96.6)Annualized bleeding rate (ABR)Overall, median (IQR)2.24 (0.00, 5.94)1.49 (0.00, 4.40)Spontaneous, median (IQR)0.00 (0.00, 1.41)0.00 (0.00, 0.00)Spontaneous joint, median (IQR)0.00 (0.00, 0.00)0.00 (0.00, 0.00)Number of injections required for resolution of a bleeding episodeMedian (IQR)1.0 (1.0, 2.0)1.0 (1.0, 1.0)Response to treatmentInjections assessed as 'excellent/good', n (%)102 (85%)163 (79.9%)

\*Number of patients with an efficacy period. Full Analysis Set patients with an efficacy period: 101 (patients with ≥ 1 day of treatment for an episodic regimen or ≥ 2 prophylactic injections for prophylactic regimens). IQR, interquartile range (25th, 75th percentile). The annualized bleeding rate is the total number of bleeding episodes during the efficacy period extrapolated to a 1‐year interval of time. Efficacy period reflects the sum of all intervals of time during which patients are treated with rFVIIIFc according to the treatment regimens of the study excluding surgical/rehabilitation periods and large injection intervals (\>28 days). Patients are included in each treatment regimen they participated in for the duration of time on that regimen and as such may appear in more than one treatment regimen.

OC 03.3 {#rth212401-sec-0028}
=======

Deciphering the Ets‐1/2‐mediated Transcriptional Regulation of F8 Gene Identifies a Minimal F8 Promoter for Hemophilia A Gene Therapy {#rth212401-sec-0029}
-------------------------------------------------------------------------------------------------------------------------------------

**R. Famà^1^, [E. Borroni]{.ul}^1^, S. Merlin^1^, S. Pignani^1^, C. Airoldi^2^, A. Cucci^1^, V. Bruscaggin^1^, S. Scardellato^1^, M. Pinotti^3^, G.E. Walker^1^, A. Follenzi^1^**

^1^Università del Piemonte Orientale, Department of Health Sciences, Novara, Italy^2^Università del Piemonte Orientale, Department of Translational Medicine, Novara, Italy^3^Università di Ferrara, Department of Life Sciences and Biotechnology, Ferrara, Italy

**Background :**A major challenge in the development of a gene therapy for hemophilia A (HA) is the selection of cell type‐ or tissue‐specific promoters to ensure factor VIII (FVIII) expression without eliciting an immune response. As liver sinusoidal endothelial cells (LSECs) are the major FVIII source, understanding the transcriptional *F8* regulation in these cells would help optimize the minimal *F8* promoter (pF8) to efficiently drive FVIII expression.

**Aims :**To investigate the modulation of F8 promoter activity and deciphering the role of Ets‐1/2 transcription factors.

**Methods :** *In silico* analyses predicted several binding sites (BS) for the E26 transformation‐specific (Ets) transcription factors Ets‐1 and Ets‐2 along the pF8. Ets‐1 and Ets‐2 or both were transfected with pF8 in ECV or HEK293T cell line and luciferase assays have been performed to study the promoter activity in response to these factors. Ets‐1/Ets‐2‐DNA binding domain mutants (DBD) were generated as well as shortened forms of pF8 carrying Ets‐BS deletion, and evaluated *in vitro* by reporter assays and *in vivo* by injecting lentiviral vectors (LV) carrying GFP or FVIII cassettes in C57Bl/6 or B6/129 hemophilic (HA) mice.

**Results :**Reporter assays demonstrated a significant up‐regulation of pF8 activity by Ets‐1 or Ets‐1/Est‐2 combination, while Ets2 alone was ineffective. Moreover, Ets‐1/Ets‐2‐DNA binding domain mutants (DBD) abolished promoter activation only when the Ets‐1 DBD was removed, suggesting that pF8 up‐regulation may occur through Ets‐1/Ets‐2 interaction with Ets‐1 bound to DNA. *In vivo*, LV delivery of GFP or FVIII cassettes driven by these promoters, led to transgene expression mainly in LSECs as well as long‐term FVIII activity without inhibitor formation.

**Conclusions :**This approach revealed the −342 bp region, where three Ets‐1 and one Ets‐2 sites were maintained, as a minimal sequence required to maintain in vitro activity and a regulated FVIII expression restricted to LSECs, representing a potential application in HA gene therapy.
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**Background :**A single infusion of AAV5‐hFVIII‐SQ (valoctocogene roxaparvovec) increased factor VIII (FVIII) levels, reduced annualized bleeding rate, and decreased FVIII utilization in clinical study participants with hemophilia A. Durable expression may be associated with presence of circularized vector DNA episomes in hepatocytes, but this has not been confirmed through liver biopsy in humans.

**Aims :**To evaluate histopathology and vector DNA form, and distribution in human liver biopsies following AAV‐hFVIII‐SQ administration.

**Methods :**Liver biopsies were obtained from 2 participants at week 201 and 140 post infusion with 6 × 10^12^ vg/kg or 4 × 10^13^ vg/kg AAV5‐hFVIII‐SQ, respectively. Biopsy samples underwent histopathological examination, in situ hybridization to detect vector genomes, and DNA extraction for molecular analyses. Levels of circular vector genomes that were full‐length or contained inverted terminal repeat (ITR) fusions were quantified using drop‐phase droplet‐digital PCR (ddPCR). Southern blotting was used to visualize circular episome configurations. Liver hFVIII‐SQ RNA levels were quantified with reverse transcription followed by ddPCR. All participants provided informed consent. Relevant ethics boards approved the protocol. BioMarin Pharmaceutical provided funding.

**Results :**Histopathological examination revealed normal liver architecture with mild steatosis and no evidence of steatohepatitis or significant inflammation in either participant. In 6 × 10^12^ vg/kg‐ and 4 × 10^13^ vg/kg‐treated participants, 1.3% and 32% of hepatocytes, respectively, stained positive for vector genomes in a pan‐lobular distribution, similar to previous observations in non‐human primates (Figure 1). Circularized full‐length vector genomes and ITR‐fusions were present as monomers and concatemers in both participants (Figure 2).

Liver hFVIII‐SQ RNA levels were 7.67 × 10^2^ copies/μg (6 × 10^12^ vg/kg‐treated participant) and 6.77 × 10^4^ copies/μg (4 × 10^13^ vg/kg‐treated participant). Analyses of additional participant biopsies will be shared at ISTH.

**Conclusions :**Mechanisms of AAV gene therapy durability are yet to be determined for hemophilia A. Here, we demonstrate persistent FVIII expression consistent with the presence of circularized, full‐length hFVIII‐SQ DNA in human liver, nearly 4 years after a single AAV5‐hFVIII‐SQ infusion.

**Figure 1** In situ hybridization of vector genome DNA (brown) in human liver biopsy samples

**Figure 2** A) Copies of circularized vector genome per diploid genome, and B) configuration of circular episomes in human biopsy samples
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**Background :**Investigational gene transfer for hemophilia A (HA) provides potential for a one‐time, life‐long disease altering therapy. While on‐going studies are promising, recent long‐term follow‐up data from the first successful HA gene transfer trial reported declining FVIII expression over time (Pasi 2020), raising concerns about the durability of AAV‐mediated liver‐directed *F8* gene transfer.

**Aims :**We present data on our initial cohorts of an ongoing Phase I/II trial investigating *SPK‐8011* for HA (data cut 1/24/2020).

**Methods :**5 adult HA males (34--52 years) with FVIII:C ≤ 2% received *SPK‐8011* at a dose of 5 × 10^11^ or 1 × 10^12^ vg/kg.

**Results :**Subjects are 106--142 weeks post‐vector. There were no study drug‐related AEs/SAEs, or transaminase elevations above normal. No subjects developed FVIII inhibitors or evidence of a FVIII cellular immune response. The 5 × 10^11^ vg/kg cohort (n = 2) had FVIII:C of 6.9--8.4%. The 1 × 10^12^ vg/kg cohort (n = 3) FVIII:C was 5.2--19.8%. Two of 3 subjects in the 1 × 10^12^ cohort were treated with reactively administered steroids for ˜7 weeks, initiated in response to declining FVIII levels without ALT elevation or positive IFN‐g ELISPOTs to capsid‐derived peptides. After achieving steady‐state FVIII expression by 8--12 weeks, there was no change in FVIII:C (Figure 1). Over the \> 2‐year observation period, there was a 95% reduction in annualized infusion rate and a 91% reduction in ABR. Post‐vector ABRs were: 0.4, 0.0, 0.4, 3.6, 0.5.

**Conclusions :**These data demonstrated no major safety concerns to date and provided support for the efficacy of *SPK‐8011* for the treatment of HA. There is no evidence of decline in FVIII expression following *SPK‐8011* after \> 2 years of follow‐up. Our data represent the longest stable expression of FVIII following gene transfer and support the ability of AAV‐mediated hepatocyte‐directed gene transfer to achieve durable FVIII expression for the potential treatment of HA.

**Figure 1** Factor VIII Levels Over Time by Participant in the 5E11 vg/kb and 1E12 vg/kg Dose Groups
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**Background :**Side effects of liver injury are characterized by alterations in primary hemostasis including thrombocytopenia and platelet function defects. However, the consequences of liver resection on platelet function are not well defined.

**Aims :**The aim of this study is to analyze platelet activity, hemostasis and thrombopoietin (TPO) signaling up to 14 days after partial hepatectomy in mice.

**Methods :** *In vitro* and *in vivo* experiments using partial hepatectomy (PHx) in wildtype and interleukin‐6 receptor (IL‐6R) knockout mice.

**Results :**Significantly decreased platelet counts following PHx operation increase to normal levels within 3 days. Simultaneously, intrinsic platelet activation was strongly reduced, due to high plasma levels of nitric oxide, prostaglandin I2 and bile acids. These factors cause an increased endogenous phosphorylation of VASP resulting in functional platelet inhibition after liver dissection. The activation defects resulted in strongly reduced thrombus formation under flow and prolonged bleeding time in the first 3 days after PHx. Increasing TPO expression in liver tissue and plasma TPO levels were measured in the early phase of regeneration mediated through activation of the Ashwell Morell (AMR) and IL‐6 receptor, leading to a JAK2‐STAT3 downstream signaling. Interestingly, genetic deletion of IL‐6R leads to a compensatory upregulation of the AMR in naive and PHx operated mice resulting in higher TPO expression and plasma levels in knockout compared to wildtype mice. Enhanced TPO production in wildtype mice leads to splenic megakaryopoiesis and moderate splenomegaly of PHx operated animals indicating high platelet turn‐over as compensatory event after PHx to overcome decreased platelet counts, defective platelet activation and platelet infiltration into the regenerating liver tissue.

**Conclusions :**These results indicate that liver dissection affects primary hemostasis and highlights the regulatory mechanisms behind TPO expression in an inflammatory and regenerative *in vivo* model that might contribute to prevent bleeding complications in patients after liver resection.

OC 04.2 {#rth212401-sec-0037}
=======

GPR56 is a Platelet Collagen‐Responsive GPCR and Hemostatic Sensor of Shear Force {#rth212401-sec-0038}
---------------------------------------------------------------------------------

**J. Yeung, R. Adili, E. Stringham, A. Vizurraga, L. Roselli, M. Yu, M. Holinstat, [G. Tall]{.ul}**

University of Michigan, Pharmacology, Ann Arbor, USA

**Background :**Circulating platelets roll along exposed collagen at vessel injury sites and respond with filipodia protrusion, shape change and surface area expansion. These events precede stable adhesion and wound‐healing hemostatic plug formation. Various glycoproteins and integrins are considered to be both collagen responders and mediators of platelet adhesion, although the kinetics of the signaling circuits emanating from these receptors do not fully account for the rapid platelet cytoskeletal changes that occur in blood flow.

**Aims :**To demonstrate the role of GPR56 in hemostasis and thrombosis..

**Methods :**Protein biochemistry, platelet aggregometry, transgenic mice and in vivo hemostasis and thrombosis models, collagen flow chamber model with human platelets.

**Results :**We report that GPR56/ADGRG1 is a platelet adhesion G protein‐coupled receptor (AGPCR) that transduces the signal from collagen and blood flow‐induced shear force to activate G protein 13 signaling for platelet shape change. AGPCRs are two‐fragment receptors that have been proposed be activated by shear force‐mediated fragment dissociation to unmask a tethered‐peptide‐agonist. We trapped the freed GPR56 N‐terminal fragment (NTF) from human plasma using collagen‐coated beads. *Gpr56* ^−/−^ mice were found to have prolonged bleeding and defective platelet plug formation. Blood perfusion over collagen demonstrated that *Gpr56* ^−/−^ platelets or platelets in human blood treated with recombinant GPR56 NTF adhered defectively at high shear. The GPR56 rNTF exhibited anti‐coagulant properties in mouse circulation.

**Conclusions :**Our work updates the hemostasis model by placing GPR56 as an initial collagen‐responder and shear‐force transducer that fulfills platelet shape change.

**Figure 1** Role of GPR56 in Platelet Action During Hemostasis
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**Background :**Ischemic stroke is a leading cause of morbidity and mortality worldwide. Recanalization of the occluded vessel is essential, but not sufficient to guarantee brain salvage. Infarcts often develop further due to a thrombo‐inflammatory process critically involving platelets and T cells, but the underlying mechanisms are unknown.

CD84 is a member of the SLAM family and acts as a homophilic cell adhesion molecule highly expressed on platelets and on different immune cell populations, where it acts a co‐receptor.

**Aims :**We aimed to assess a potential contribution of CD84 to infarct growth following experimental stroke.

**Methods :**Mice lacking CD84 either constitutively or on their platelets were subjected to the transient middle cerebral artery occlusion (tMCAO) model and immune cell infiltration into the brain, as well as infarct sizes were determined. Wild‐type (WT) and *Cd84* ^−/−^ CD4^+^ T cells were adoptively transferred into lymphocyte‐deficient mice (*Rag1* ^−/−^) prior to tMCAO. The motility of WT and *Cd84* ^−/−^ T cells in response to platelet releasate or recombinant CD84 was measured *in vitro*. CD84 expression on human platelets (determined locally in the ischemic brain and systemically) and stroke severity were assessed in a small clinical cohort.

**Results :** *Cd84* ^−/−^ mice, as well as mice lacking CD84 on either platelets or T cells displayed reduced cerebral CD4^+^ T cell infiltration and less occluded vessels following experimental stroke, resulting in reduced neurological damage. Platelet‐derived soluble CD84 enhanced motility of WT, but not of *Cd84* ^−/−^ CD4^+^ T cells *in vitro* suggesting homophilic CD84 interactions to drive this process. In a clinical study, human arterial blood directly sampled from the ischemic cerebral circulation indicated local shedding of platelet CD84. Moreover, high platelet CD84 expression levels were associated with poor outcome in stroke patients.

**Conclusions :**These results establish CD84 as a critical pathogenic effector and thus a potential pharmacological target in ischemic stroke.
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**Background :**Platelets are best known for their ability to limit blood loss after vascular injury. Previous studies have shown that platelets may also contribute to the maintenance of endothelial cell health in homeostatic conditions even in absence of any injury or inflammation.

**Aims :**Examine the contribution of platelets, their secretion machinery and platelet signaling pathways in maintenance of homeostatic vascular barrier function by studying changes in vascular permeability in thrombocytopenic and transgenic mice.

**Methods :**Vascular barrier function was assessed by measuring the extravasation of fluorescent dextrans and albumin from capillaries and post‐capillary venules in the murine skin microvasculature and meninges using multiphoton microscopy *in vivo*. Mice were rendered severely thrombocytopenic by immunodepletion or administration of busulifan.

**Results :**Thrombocytopenia induced by immunodepletion or administration of busulfan caused a reduction in barrier function detectable as increased extravasation of 40 kDa dextran, but not albumin from dermal microcirculation. This reduction in barrier function required more than 4 hours to emerge and was reversed with partial recovery of circulating platelet counts. Increased dextran extravasation was also observed in mice lacking platelet dense granule and secretion machinery, glycoprotein (GP) VI, or its downstream signaling effector phospholipase C (PLC)g2. No increase in dextran extravasation was observed in mice lacking a‐granules, C type lectin receptor 2 (CLEC‐2) or protease activated receptor 4 (PAR4), each of which is important for hemostasis or preventing inflammatory bleeds. Similar barrier dysfunction was also noted in meningeal vessels, but not in intracerebral vessels, in the absence of platelet GPVI.

**Conclusions :**Our results highlight an underappreciated role of platelets in maintaining vascular barrier function which requires GPVI signaling and dense granule secretion. This homeostatic role is distinct from the platelet response to injury and inflammation. The effects of thrombocytopenia on vascular barrier are delayed and emphasize the differences between the role of platelets in supporting homeostasis versus hemostasis.

**Figure 1** Thrombocytopenia or *GPVI* deficiency increase vascular leakage. Images taken post dextran infusion in mice (A) are thrombocytopenic (B) *GPVI* ^−/−^
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**Background :**Store‐operated calcium entry (SOCE) is the major route of Ca^2+^ influx in platelets. The Ca^2+^ sensor stromal interaction molecule 1 (STIM1) triggers SOCE by forming puncta structures with the Ca^2+^ channel Orai1 and the inositol trisphosphate receptor (IP3R), thereby linking the endo‐/sarcoplasmic reticulum to the plasma membrane during SOCE. Several proteins in various cell types have been identified to stabilize this complex and to modulate Ca^2+^ influx.

**Aims :**To identify and characterize novel interaction partners of STIM1 in platelets.

**Methods :**We screened for novel interaction partners of STIM1 in platelet lysates using a recombinant STIM1‐C‐tail protein, affinity chromatography and mass spectrometry. Subsequently, we generated megakaryocyte‐ and platelet‐specific bridging integrator 2 (BIN2) knockout mice (*Bin2* ^*fl/fl‐Pf4Cre*^) and assessed the role of BIN2 in a broad range of *in vitro* platelet experiments and microscopic assays as well as in *in vivo* models of arterial thrombosis and thrombo‐inflammatory brain infarction.

**Results :**Using affinity chromatography to screen for STIM1 interacting proteins in platelets we identified BIN2, a protein of the BAR domain superfamily. BIN2 deficiency resulted in a markedly reduced Ca^2+^ store release and hence reduced Ca^2+^ influx in response to GPCR as well as (hem)ITAM coupled agonists. Although platelet phospholipase C (PLC) activation and IP3 production were normal in BIN2‐deficient platelets, impaired IP3R function was detected after stimulating with IP3. Interestingly, thapsigargin mediated SOCE was also defective, indicating a complex interplay between BIN2, IP3R and STIM1/Orai1 complex. These defects translated into impaired thrombus formation under flow and a protection of *Bin2* ^*fl/fl,Pf4‐Cre*^ mice in models of arterial thrombosis, hemostasis and stroke without increasing the risk of intracranial hemorrhage.

**Conclusions :**BIN2 plays a key role in the activation of IP3R and STIM1 during Ca^2+^ store depletion and SOCE in platelets. These results establish BIN2 as a central regulator of platelet activation in thrombosis and thrombo‐inflammatory disease settings.
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**Background :**Factor XII (FXII) zymogen activation requires cleavage in the activation loop, which can be executed by plasma kallikrein (PKa), activated FXII (autoactivation) or plasmin. Human mutations in FXII cause acute‐ (T309K/R) or chronic inflammatory disease (W268R). The former mutations result in inappropriate truncation events, while the latter mutation disturbs protein conformation. In both cases, the activation loop of FXII becomes exposed in the absence a contact surface.

**Aims :**To identify the domain that shields the activation loop.

**Methods :**Wild‐type FXII (WT‐FXII) 7 consecutive N‐terminal domain‐deleted FXII variants (Fig. 1), as well as active‐site incapacitated (S544A) or T309K variants were expressed in HEK293F cells. We studied enzyme activation/activity and surface binding in chromogenic substrate assays and by Western blotting.

**Results :**FXII mutants that lack the Fibronectin type II domain (FnII; Δ1--71 and onwards), generate activation fragments and display spontaneous amidolytic activity. This results from autoactivation, since matching FXII S544A variants display no fragmentation. Furthermore, deletion of the FnII domain enhances FXII activation by PKa or plasmin.

Pull‐down experiments show that the first EGF‐like domain is essential for binding to polyphosphate or kaolin. Surface binding of WT‐FXII that contains the FnII domain increases activation by PKa (˜3×). Without the FnII domain, surface binding no longer enhances FXII activation by PKa.

Human FXII mutation T309K causes acute inflammation by enabling enzymatic release of the protease domain. Full‐length FXII‐T309K develops increased activity compared to WT‐FXII after exposure to plasmin. Conversely, in the absence of the FnII domain, the T309K mutation (FXII‐T309K‐Δ1--71) fails to further increase activity after exposure to plasmin. This suggests that the pathogenic gain of function of T309K mutation is caused by enzymatic elimination of the FnII domain.

**Conclusions :**Cumulatively, our data suggest that the FnII domain shields the activation loop of FXII, ensuring zymogen quiescence. Pathogenic mutations that interfere with this function accelerate FXII activation.

**Figure 1** Factor XII domain organization and truncation strategy
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**Background :**Extracorporeal membrane oxygenation (ECMO) is a lifesaving therapy for many pediatric patients but requires anticoagulation due to contact activation of blood. Despite the use of unfractionated heparin (UFH), significant thrombotic and hemorrhagic complications are common and contribute to mortality. A more selective anticoagulation strategy might provide similar thromboprevention while improving hemostasis compared to UFH.

**Aims :**Thromboprevention and hemorrhage in a high‐fidelity piglet model of pediatric venoarterial ECMO were compared between the standard of care (UFH) and RB006, a novel and highly specific RNA aptamer‐based factor IXa (FIXa) inhibitor.

**Methods :**Ten Yorkshire piglets weighing 4--5 kg were anesthetized and cannulated via R carotid and jugular to venoarterial ECMO for 12 hours. Five piglets were treated with a single dose of RB006 (target plasma concentration 0.5 μM) at cannulation, and five control piglets were treated with UFH infusion titrated to a goal ACT of 180--220 s. Arterial blood gas (ABG) analysis and ACT were performed hourly. Primary outcomes were ECMO flows and blood transfusions to maintain hematocrit \> 20%. Clinical bleeding and oxygenator clot burden were documented by photography and electron microscopy.

**Results :**All 10 circuits remained patent with excellent flows throughout the 12‐hour run. RB006 transfusion requirements were significantly less than UFH (3.9 mLs/kg vs. 47.4 mLs/kg, *P* = 0.0061). Consistent with clinical experience, all 5 UFH control animals slowly bled from instrumentation sites, while RB006 animals were hemostatic after cannulation. A few small macroscopic clots were visible on all 10 oxygenators at run completion, and SEM revealed significant adherent microscopic clot on 2/3 UFH and 0/3 RB006 oxygenators, with minimal foci of clot on the remainder.

**Conclusions :**Inhibition of the final step of the contact pathway with a novel RNA aptamer inhibitor of FIXa represents a rational approach to anticoagulation in a piglet model of pediatric ECMO. Its use greatly improved hemostasis while providing similar thromboprevention compared to the standard of care.

**Figure 1** LEFT: Circuit schematic. TOP RIGHT: Mean flows for 12 hours run, ideal flows in gray box. BOTTOM RIGHT: Scanning EM comparison of oxygenator clot burden

**Figure 2** LEFT: Mean transfusion volume to maintain hematocrit \> 20%, P = 0.0061. RIGHT: Bleeding at instrumentation sites at conclusion of 12 hours run
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**Background :**Deep vein thrombosis (DVT) is a debilitating and sometimes life‐threatening disease that results from platelet and leukocyte accumulation at the vessel wall in a process known as thromboinflammation. Activated neutrophils release neutrophil extracellular traps (NETs) composed of DNA and histones, and destruction of NETs by DNase, or prevention of their formation, protects mice from DVT. Inflammasomes are molecular complexes, which set an inflammatory cascade in motion by activating caspase‐1, leading to IL‐1β activation.

**Aims :**In this project, we aimed to investigate the bidirectional interactions between inflammasomes and NETs in the context of murine DVT.

**Methods :**DVT was induced in C57BL/6 male mice by partial ligation of the inferior vena cava (IVC). Thrombus formation was evaluated at 48 hours post‐surgery.

**Results :**Following IVC stenosis, we detected active caspase‐1 in approximately 50% of platelets located within thrombi, and 10% of platelets in the circulation. Leukocytes containing active caspase‐1 were restricted to the thrombus. Intravital imaging revealed the presence of both NETs and active caspase‐1 signal in the IVC post stenosis. Histones and neutrophils undergoing NETosis induced caspase‐1 activation and aggregation in washed human platelets. Image analysis of cells stimulated *in vitro* showed that most inflammasome‐containing cells were localized within NETs, whereas NETosis occurred in the absence of inflammasomes. This implies that NETs likely serve as a basis for and a primary inducer of inflammasomes rather than vice versa. In thrombi, NETs and inflammasomes were colocalized. Inhibition of caspase‐1 by a specific inhibitor Ac‐YVAD‐cmk reduced thrombosis incidence and NETosis in thrombi.

**Conclusions :**Collectively, we show that NET formation and inflammasome assembly are interconnected events in DVT. We suggest that these form an inflammatory circuit, resulting in IL‐1β activation, which creates a positive feedback loop promoting further activation of platelets and endothelial cells. Our work provides a rationale for targeting this circuit for prevention of venous thrombosis.
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**Background :**Intracerebral hemorrhage (ICH) is the most severe stroke subtype. Early hematoma growth occurs in one third of patients within 3 hours of stroke onset and is predictor of poor outcome. Clinical trials have shown that untargeted hemostatic therapy with rFVIIa reduced hematoma growth but conveyed an unacceptable rate of side effects. Targeted treatments able to selectively promote hemostasis at the site of bleeding are therefore necessary. Previous studies reported that monocyte‐derived microparticles (mMPs) bearing tissue factor (TF) accumulate during thrombus formation and promote thrombin generation.

**Aims :**To generate large amount of pro‐coagulant MPs to be used as hemostatic patches in preclinical models of ICH.

**Methods :**Monocytic cell‐line THP‐1 were grown in bioreactors and treated with TNF to generate TF^+^ mMPs. Isolated mMPs were characterized by laser‐scanning confocal microscopy and flow cytometry. Functional studies were performed using human plasma clotting assays and TF‐activity. In vivo, mice received an intrastriatal injection of collagenase VII to promote intraparenchymal hemorrhage. 30 minutes thereafter, exogenous mMPs were injected intravenously. Hematoma volume was quantified by MRI at 24 hours and neurological deficits were measured at 4 and 24 hours post‐stroke.

**Results :**Large amounts of mMPs were generated in supernatants from TNF‐stimulated monocytes in bioreactors. Those MPs presented monocyte‐specific characteristics: a mean size of 430 nm and a high pro‐coagulant activity reducing the clotting time in a dose‐ and TF‐dependent manner. In preclinical studies of ICH, intravenous injection of mMPs improved stroke outcome in a dose‐dependent manner. mMPs at 1 mg/kg prevented hematoma growth by 43% and improved neurological score at 4 and 24 hours compared to control mice (*P* \< 0.01, n = 15/group). This beneficial effect was also present in a more severe model of ICH in enoxaparin‐treated mice. Immunohistological studies revealed accumulation of fluorescently‐labeled mMPs at the bleeding site.

**Conclusions :**Exogenous microparticles bearing TF improve outcome after collagenase‐induced ICH by acting as intravascular patches.
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**Background :**Thrombin is central to haemostasis with both pro‐ and anticoagulant functions. Interest in interactions between complement and coagulation is increasing. We hypothesised that the complement regulator factor H (FH) influences the action of thrombin.

**Aims :**To determine the effect of FH on thrombin pro‐ and anticoagulant functions.

**Methods :**Tail‐bleeding time and blood loss was measured in FH knockout mice. FH‐depleted human plasma was used to measure activated partial thromboplastin time (aPTT) and clot formation was monitored in fibrin generation turbidity assays. Thrombin‐mediated activated protein C (aPC) generation was measured in the presence and absence of thrombomodulin. Thrombin‐FH binding was investigated in a binding assay and affinity was measured using surface plasmon resonance.

**Results :**Tail‐bleeding time in FH knockout mice was 804 ± 550 seconds, compared to 196 ± 305 seconds in wild type (*P* = 0.017). The aPTT in FH‐depleted human plasma was prolonged (107 ± 5 seconds) and restored (76 ± 2 seconds) by the re‐addition of FH into depleted plasma (*P* = 0.002). FH enhanced thrombin‐mediated fibrinogen cleavage and fibrin clot generation by shortening lag time (100 nM FH 5.3 ± 0.6 minutes; Control 22.7 ± 0.6 minutes, *P* = 0.002) and increasing the rate of clot formation (*V*(OD405\*min^‐1^); 100 nM FH 0.048 ± 0.003; Control 0.008 + /‐0.0001, *P* = 0.002) in a concentration dependent manner. Thrombin activation of protein C was shown in a FH concentration dependent manner in the presence (Kd˜2.14 ± 0.26 nM FH, *P* = 0.0006) or absence (Kd˜17.04 ± 2.67 nM FH, *P* = 0.0004) of thrombomodulin. Thrombin binding affinity with FH was KD˜23 nM. FH complement regulatory function was not altered by thrombin binding.

**Conclusions :**Complement FH is a novel cofactor for thrombin that enhances pro‐ and anticoagulant mechanisms. There was significant impact on in vivo bleeding, rate of fibrin clot generation and activation of protein C. These data highlight the importance of interactions between coagulation and complement systems and the potential impact of their imbalance or dysregulation in disease.

**Figure 1** Absence of factor H inreases bleeding time in factor H KO mice and prolongs aPTT in human factor H‐depleted plasma

**Figure 2** Factor H enhances rate of fibrin clot formation and protein C activation
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**Background :**Platelets migrate from bloodstream into tumor microenvironment and support tumor growth. But the full understanding of trans‐endothelial platelet extravasation in cancer remains limited. The complex interactions between blood cells, endothelium and tumor that take place *in vivo* require dissectible analysis and visualization that animal models don\'t always provide. Therefore, a humanized experimental model that predicts tumor‐vascular signaling, includes blood constituents, and provides mechanistic insight is required.

**Aims :**We established an ovarian tumor‐vessel‐blood‐flow integrated *in vitro* biosystem (OvCa‐Chip) and evaluated critical platelet‐mediated processes in ovarian cancer. We tested the hypothesis that tumor cells release signals that result in nearby vascular endothelium to lose its barrier integrity, following which platelets extravasate into the tumor. Additionally, platelets interact with tumor Galectin‐3 through their GP‐VI receptors and this interaction results in tumor proliferation.

**Methods :**The OvCa‐Chip consisted two adjacent microfluidic chambers separated by extracellular matrix. One chamber was lined with ovarian cancer cells and in the second chamber, we cultured primary endothelial cells on all sides thus forming a vessel constituting perfusion of platelet‐rich‐plasma at physiological flow rates for 5 days. We performed live‐cell imaging along with analysis of cytokines in effluents, transcriptomics, cell cycle analysis of tumors and biochemical investigation of surface‐receptor protein interactions.

**Results :**OvCa‐Chip revealed key role of tumor‐shed cytokines in activation of vascular *Src/FAK/Akt* signaling, that eventually downregulated transcription‐factor *VE‐PTP* and inhibited formation of *VE cadherin‐βcatenin complex,* crucial for endothelial barriers. Platelets transmigrated into tumors via communication with endothelial *Tie‐2, Pyk‐1 and Rac‐1* and post extravasation, interacted with tumor *Galectin‐3* via *GPVI* that triggered secretion of tumor growth factors and metastasis. Correspondingly, atorvastatin treatment and inhibition of Galectin3‐GP‐VI interaction resulted in reduced platelet extravasation and tumor growth.

**Conclusions :**Subsequent confirmation of these data with cancer patient biopsies altogether established OvCa‐Chip as a platform to model platelet & vascular function in cancer and new therapeutics.

**Figure 1** OvCa‐Chip: A new experimental model to investigate platelet and vascular function in cancer
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**Background :**Tissue Factor (TF) protein isoforms -- full‐length (flTF) and alternatively spliced (asTF) -- are often overexpressed in cancer. Previously, we have shown that a rabbit monoclonal antibody specific for human asTF, termed RabMab1, disrupts binding of asTF to beta‐integrins and suppresses proliferation of breast and pancreatic cancer cells expressing endogenous flTF and asTF.

**Aims :**1) Humanize RabMab1 and evaluate its systemic pharmacokinetics. 2) Evaluate biological effects of humanized RabMab1 in an orthotopic murine model of pancreatic ductal adenocarcinoma (PDAC).

**Methods :**Variable regions of RabMab1 heavy and light chains were used to generate chimeric RabMab1 (c‐RabMab1). Substitutions of species‐specific residues were then carried out to produce fully humanized RabMab1 (h‐RabMab1). Pharmacokinetics were assessed via intravenous injections of c‐RabMab1 and h‐RabMab1 in mice. For anti‐tumor efficacy studies, 1 × 10^6^ Pt45.P1 cells (a high grade, flTF+/asTF+ human PDAC cell line) were orthotopically implanted into nude mice. Treatment with 18 mg/kg h‐RabMab1 (n = 9), 18 mg/kg hIgG1 isotype control (n = 7), or vehicle (n = 5) began 10 days post‐tumor cell implantation and continued for 44 days. Upon sacrifice, tumor volume was measured and tissue assessed by western blotting, immunohistochemistry, and RNA‐seq.

**Results :**The elimination half‐life of h‐RabMab1 (908 hours) was markedly longer when compared to that of c‐RabMab1 (280 hours). Tumors in mice treated with h‐RabMab1 were 60% smaller than tumors in either control group. Immunohistochemistry revealed significantly lower levels of CD31, CD206, and Ki67 in the h‐RabMab1 group. RNA‐seq analysis (https://toppg​ene.cchmc.org) revealed upregulation of various molecular function linked pathways with the expression levels of IL‐18, somatostatin, and TGFbeta2 significantly higher in the h‐RabMab1 group; expression of the mesenchymal marker vimentin was suppressed in the h‐RabMab1 group (all validated by qRT‐PCR).

**Conclusions :**Our first‐in‐class anti‐asTF antibody is effective at stemming PDAC growth when administered intravenously to mice with pre‐formed tumors. These findings pave the way for future clinical development of h‐RabMab1.
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**Background :**Angiogenesis in Glioblastoma (GBM), a highly aggressive brain tumor, is poorly organized causing tumor cell necrosis, hemorrhage and clotting.

**Aims :**To study the role of clotting in GBM progression.

**Methods :**Using immunohistochemistry, we compared fibrin formation in tumor samples from patients with GBM to those with astrocytoma 2 and 3. Freshly isolated tumor cells from patients with GBM or astrocytoma were cultured in 3D fibrin *in vitro* and assessed for proliferation and invasion. To assess the role of clotting *in vivo*, we implanted GBM cells orthotopically into mice and tracked brain tumor formation by MRI. To trace fibrin formation in brain tumors *in vivo*, GBM‐bearing mice were injected intravenously with a fluorescein‐conjugated clot‐binding peptide (FITC‐CGLKIQKNEC) and probed for tumor binding using fluorescence endoscopy *in situ* or fluorescence microscopy on tissue sections *ex vivo*.

**Results :**Immunohistochemistry of patient tissues revealed an upregulation of clot formation in the interstitial spaces of GBM compared to lower grade astrocytoma and normal brain, which was fibrin‐free. Using a 3D culture system *in vitro*, we determined that fibrin supports growth and infiltration of glioblastoma stem cells based on expression of integrin β3 and fibronectin. *In vivo*, we detected an initial delay of GBM development in clotting‐deficient hemophilia mice and observed accelerated brain tumor growth after implanting GBM cells into mice in conjunction with clotted plasma. To assess fibrin formation in glioblastoma *in vivo*, we injected GBM‐bearing mice intravenously with FITC‐CGLKIQKNEC, which generated a strong green fluorescence in GBMs *in situ* and isolated brain tumor tissue *ex vivo*.

**Conclusions :**Our data demonstrate specific upregulation of fibrin in GBM, which promotes infiltration and proliferation of glioblastoma stem cells. Furthermore, we present a strategy to identify fibrin in the tumor extracellular matrix as a possible means to identify GBM progression *in vivo*.
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**Background :**Diabetic nephropathy (dNP) is the leading cause of end stage renal disease worldwide. A major therapeutic obstacle in dNP is the failure of renal recovery upon improved blood glucose levels, a phenomenon known as hyperglycemic memory. Epigenetic changes were linked to this memory but the actual mechanisms remain largely elusive. Activated protein C (aPC) has been shown to epigenetically restrict ROS generation in dNP. However, whether aPC could reverse the hyperglycemic memory is currently not known.

**Aims :**To identify mechanisms contributing to the hyperglycemic memory in dNP and whether aPC can therapeutically reverse the hyperglycemic memory.

**Methods :**Two mouse models of type 1 and 2 diabetes with established dNP were used. Blood glucose was normalized using an SGLT2‐inhibitor. RNA‐seq was used to evaluate pathways involved in hyperglycemic memory. In vitro and in vivo studies were conducted to determine mechanistic and translational relevance of aPC role targeting the hyperglycemic memory.

**Results :**The senescence‐associated cyclin dependent kinase inhibitor p21 was among the top persistently induced genes despite blood glucose lowering while protein C gene was downregulated. Sustained tubular expression of p21 was confirmed in diabetic mice and in human patients despite blood glucose lowering. Sustained p21 expression was linked with demethylation of its promoter and reduced DNA methyl transferase 1 (DNMT1) expression. In silico analysis identified miR‐148a as a potential regulator of DNMT1. Increased tubular senescence and interstitial fibrosis were confirmed in diabetic mice with genetic deficiency of protein C activation. Substituting aPC or mimicking biased aPC‐signaling (parmodulin‐2) in addition to normalizing blood glucose levels reversed sustained tubular p21 expression, tubular senescence, and renal damage in mice with established dNP via regulating miR‐148a‐dependent DNMT1 activity.

**Conclusions :**Epigenetically sustained p21‐expression and associated senescence contribute to the hyperglycemic memory in dNP. This pathogenic mechanism can be targeted by mimicking aPC signaling.
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**Background :**Transfusion‐related acute lung injury (TRALI) remains a major cause of transfusion‐related fatalities. TRALI can be provoked by transfusion of blood products containing allogeneic antibodies targeting cells of the recipient. The involvement of Fcγ receptors in this type of TRALI has been poorly assessed. FcγRIIA/CD32A is an activating low affinity receptor for IgGs expressed on human platelets and immune cells, whereas no corresponding ortholog is present in mice.

**Aims :**Evaluate the contribution of CD32A in a model of immunological TRALI in transgenic mice expressing this human receptor.

**Methods :**Antibody‐mediated TRALI was induced in control mice (WT) and mice transgenic for human CD32A (CD32A^+^) by lipopolysaccharide priming followed by administration of a recombinant humanized anti‐MHC I monoclonal antibody (derived from clone 34‐1‐2S).

**Results :**TRALI responses were more severe in CD32A^+^ than in WT mice in terms of pulmonary edema and mortality, which reached 90% in CD32A^+^ versus 40% in WT animals (n = 10, \*\**P* = 0.0027, log‐rank test). Soon after induction of TRALI, the drop in platelet count worsened in CD32A^+^ compared to WT mice. Moreover, massive release of platelet granule contents was observed only in the peripheral blood of CD32A^+^ animals. Preventive platelet depletion suppressed the exacerbation of TRALI observed in CD32A^+^ mice, whereas it did not impact TRALI in the WT. Long term treatment with the selective serotonin reuptake inhibitor fluoxetine, to deplete the serotonin content of platelet granules, selectively abolished the aggravation of lung edema in CD32A^+^ mice. Blockade of 5‐hydroxytryptamine 2A receptors with sarpogrelate also prevented the exacerbation of this edema in CD32A^+^ animals when the drug was administered before and after the induction of TRALI.

**Conclusions :**Our findings identify platelet CD32A as a critical determinant of the severity of antibody‐mediated TRALI and provide a rationale for the design of serotonin pathway targeting strategies to attenuate immunological TRALI in patients.
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**Background :**Most patients with immune‐mediated thrombotic thrombocytopenic purpura (iTTP) develop autoantibodies targeting a cryptic epitope, composed of residues R568/F592/R660/Y661/Y665 in the spacer domain of ADAMTS13. Conservative substitutions of these residues resulted in a gain‐of‐function (GoF; R568K/F592Y/R660K/Y661F/Y665F) ADAMTS13, which exists in an open conformation. It has been suggested that interactions between the C‐terminal CUB domains and the spacer domain maintain ADAMTS13 in a closed conformation. A recent study has shown that ADAMTS13 circulates in open conformation during the acute phase of iTTP, suggesting that conformational changes of ADAMTS13 contribute to the pathogenesis of iTTP.

**Aims :**Our aim is to investigate these conformational changes by modelling the closed conformation of ADAMTS13 *in silico*, predict the CUB domain residues which keeps ADAMTS13 in closed conformation and open ADAMTS13 *in vitro* by mutating these predicted residues.

**Methods :**YASARA Structure tool was used for homology modelling of the C‐terminal CUB domains. Domain interactions between the spacer domain and CUB domains were studied by HADDOCK protein‐protein docking. WT‐ ADAMTS13 was subjected to molecular dynamics simulations and binding free energy calculation with AMBER16. Selected residues were further mutated and the impact of these mutations on the conformation was investigated in an ELISA.

**Results :**Among different possible conformations of the spacer‐CUB domains complex, a pose which is in full agreement with the experimental data was obtained (Figure 1). Our model suggested that several CUB1 and CUB2 domain residues interact with spacer domain residues which included residue D1240. To validate our model, we monitored the conformation of an ADAMTS13 variant in which D1240 was replaced by an alanine. The resulting D1240A variant appeared to be present in an open conformation.

**Conclusions :**Overall, we have established an integrative approach by combining structural bioinformatics and experimental information to discover ADAMTS13‐CUB domain residues which are critical for maintaining ADAMTS13 in a closed conformation.

**Figure 1** Closed‐conformation model between Cys‐rich/Spacer and CUB1‐2 domains
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**Background :**Acquired thrombotic thrombocytopenic purpura (aTTP) patients suffer in 80% of the cases from an anti‐ADAMTS13 autoantibody induced severe ADAMTS13 deficiency (immune‐mediated TTP). However, in the remaining 20% of aTTP patients, no anti‐ADAMTS13 autoantibodies are detected. In those patients, the cause of ADAMTS13 deficiency is unknown and aTTP is often secondary to an infection, cancer or transplantation. We recently showed that immune‐mediated aTTP patients have an open ADAMTS13 conformation, which is induced by the anti‐ADAMTS13 autoantibodies. To further validate open ADAMTS13 as a novel biomarker for the immune‐mediated form of aTTP, it is essential to study the ADAMTS13 conformation in the plasma of acute aTTP patients who did not have detectable anti‐ADAMTS13 autoantibodies.

**Aims :**Determine ADAMTS13 conformation in plasma of acute aTTP patients without and with anti‐ADAMTS13 autoantibodies in their plasma.

**Methods :**Acute aTTP plasma samples without (n = 102) or with (n = 49) anti‐ADAMTS13 autoantibodies were selected. ADAMTS13 antigen and ADAMTS13 conformation was determined using in‐house developed ELISA\'s.

**Results :**ADAMTS13 antigen levels were higher in the 102 plasma samples without detectable anti‐ADAMTS13 autoantibodies (0.22 ± 0.13 μg/mL) than in the 49 samples with anti‐ADAMTS13 autoantibodies (0.09 ± 0.14 μg/mL; Mann‐Whitney *P* \< 0.0001). ADAMTS13 conformation could be determined in 95 samples without and 30 samples with anti‐ADAMTS13 autoantibodies (ADAMTS13 antigen levels \> 0.03 μg/mL). Interestingly, ADAMTS13 conformation was closed in 78 of the 95 (82%) aTTP plasma samples without detectable anti‐ADAMTS13 autoantibodies. As expected, ADAMTS13 conformation was open in the majority of the aTTP samples (77%, 23/30) with anti‐ADAMTS13 autoantibodies.

**Conclusions :**Our data suggests a different mechanism of ADAMTS13 deficiency in aTTP patients without detectable anti‐ADAMTS13 autoantibodies compared to immune‐mediated aTTP patients, since their ADAMTS13 antigen levels are higher and ADAMTS13 conformation is closed. Our data further validate open ADAMTS13 as a novel biomarker for the immune‐mediated form of aTTP.
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**Background :**Follow‐up data from the International Hereditary TTP Registry show a high incidence of acute events despite regular plasma prophylaxis in many hTTP patients.

**Aims :**We evaluated whether the events occurring under regular prophylaxis were less severe (e.g. only laboratory abnormalities), compared to events in patients not treated prophylactically.

**Methods :**We scored the severity of 109 acute survived events plus 4 acute lethal events (score 1--5, according to Falter et al.\*, slightly modified, Table 1) in 87 hTTP patients and compared the severity of events occurring with or without prophylactic treatment (Table 2).

**Results :**Of 87 confirmed hTTP patients with prospective follow‐up, 41 survived 109 acute events, with a median time between onset of symptoms to treatment of 0 days (range 0--4 days) and median duration to recovery of 4 days (range 0--43 days). Thus, 87/109 (80%) survived events were immediately recognized. 74/109 events occurred in 29 patients under prophylaxis, and 35/109 events in 16 patients not under prophylaxis. The severity of acute events occurring under prophylaxis versus those occurring in the absence of prophylaxis was not different (Table 2). Nevertheless, our data show that in some patients, the introduction of regular plasma prophylaxis after the occurrence of severe acute events was beneficial. In fact, three of our patients have not experienced any additional severe event(s) (e.g. strokes and transient ischemic attacks) since the introduction of regular prophylaxis. Contrarily, discontinuation of regular prophylaxis was followed by severe acute events (e.g. strokes, and even death) in two other patients.

**Conclusions :**Currently used plasma prophylaxis schedules are not sufficiently effective to prevent the occurrence of acute events in hTTP patients. Additional prospective follow‐up and scoring of acute events will improve future treatment in [hTTP](http://hTTP).

**Table 1** Severity score for hTTP events, slightly modified from Falter et al. (Thromb Haemost 2018;118:1743‐51)1 = laboratory abnormalities onlySome of these laboratory abnormalities: •thrombocytopenia •decreased hemoglobin, red blood cells or hematocrit •decreased haptoglobin •increased LDH •increased bilirubin (indirect bilirubin) •increased reticulocytes •presence of schistocytes2 = mildLaboratory abnormalities plus at least one of the following clinical manifestations: •petechiae or bleeding, hematomas, ecchymoses •cephalgia, vertigo, nausea •fatigue, drowsiness, weakness, •(sub)‐febrile temperatures, shivering •gastrointestinal symptoms (vomiting, abdominal pain, diarrhea)3 = moderateLaboratory abnormalities plus at least one of the following clinical manifestations: •micro‐ or macro‐hematuria •jaundice •tachycardia, dyspnea •reversible dys‐or paresthesia, visual field defects, •impaired consciousness (somnolence, stupor), disorientation4 = severeLaboratory abnormalities plus at least one of the following clinical manifestations: •transient ischemic attack •stroke with aphasia and/or paresia and or apraxia and/or ataxia •acute myocardial infarction •coma, seizure •acute renal failure •multi organ failure •in case of pregnancy: abortion or still birth, premature delivery5 = lethalhTTP event with fatal outcome **Table 2** Severity of acute events occurring while patients were under prophylactic treatment or notSeverity scoreEvents under Prophylaxis (n = 76\*)Events not under Prophylaxis (n = 37\*)1 = laboratory abnormalities only11 (15%)4 (11%)2 = mild46 (60%)23 (62%)3 = moderate9 (12%)2 (5.5%)4 = severe8 (10.5%)6 (16%)5 = lethal\*2 (2.5%)2 (5.5%)

\*Sum of all survived acute events plus lethal events
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**Background :**Severe deficiency of ADAMTS13 activity resulting from autoantibodies is the primary cause of immune thrombotic thrombocytopenic purpura (iTTP). Approximately 30% of iTTP patients (pts) may experience disease exacerbation and/or relapse. However, a reliable biomarker that predicts disease recurrence is still lacking.

**Aims :**The present study investigated the role of ADAMTS13 activity in predicting recurrence of iTTP.

**Methods :**The German Federal Ministry of Education/Research (BMBF) supported our registry, approved by the Ethics Committee. Pts with written informed consent were consecutively enrolled (acute bout or remission). Prospective follow up with ADAMTS13 activity measurement was planned at 3‐month‐intervals. The predictive value of ADAMTS13 activity was assessed using Cox regression.

**Results :**From 07/2016 to 12/2019, 103 iTTP‐ pts were enrolled and followed for 140--1271 days (median 1041), 85 (20--86 years, 64 female) had at least two visits. 13 Pts relapsed. During observation period 44/85 pts had continuously normal ADAMTS13 activity (≥50%), none of them relapsed. 2 Pts had ADAMTS13 activity continuously between 25--50%, none relapsed. One patient hat ADAMTS13 activity continuously between 10--25% and did not relapse. 9 pts had ADAMTS13 activity continuously \< 10%, 8 relapsed so far. 30 Pts had undulating parameters of ADAMTS13 activity and did not relapse. 10/85 pts showed a steep decline of ADAMTS13 activity, 5 relapsed. 4 received preemptive rituximab. A reduction by at least a factor 2 within 3 months (values ≥ 50% to \< 50%) showed a strong association with occurrence of relapse (HR = 11.26 95% CI 3.66--34.62, *P* \< 0.0001). Baseline ADAMTS13 activity, age and sex were not found to be significantly associated with relapse.

**Conclusions :**Longitudinal quarterly assessment of ADAMTS13 activity is of critical value for predicting iTTP recurrence. These results suggest the need for additional off‐label therapeutic coverage (rituximab, corticosteroids, caplacizumab) to prevent recurrence in the long‐term management of patients with iTTP.
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**Background :**CAPS is a fulminant variant of antiphospholipid syndrome characterized by multi‐organ thrombosis and subsequent failure. Traditionally, a combination treatment approach has been adopted which consisted of anticoagulation (AC), glucocorticoids (GC), plasma exchange (PEX) and/or intravenous immunoglobulins (IG). However, CAPS mortality rates remain high despite this approach. Several reports and case series have demonstrated the primary and salvage activity of Rituximab (RTX) and Eculizumab (ECL) in CAPS.

**Aims :**We conducted this analysis to provide an updated description of the impact of current treatment approaches on the CAPS outcomes.

**Methods :**We compiled a pooled CAPS database. Frequency tables, Chi‐squared tests, and Fisher\'s exact tests were used to assess the effect of therapeutic approaches on the clinical outcomes.

**Results :**Our database consisted of 453 cases. Mortality rates for the following combinations were: 37% for AC/GC, 20% for AC/GC/PEX, 27% for AC/GC/IG, 31% for AC/GC/PEX/IG, 17% for AC/GC/PEX/IG/RTX, and 20% for AC/GC/PEX/IG/RTX/ECL. Mortality of all RTX‐based combinations was 17% whereas that of ECL‐based combinations was 6%. ECL successfully salvaged RTX failures in 77% of the time. Compared to AC/GC, AC/GC/PEX, RTX‐based, and ECL‐based combinations had significant lower mortality. When compared to AC/GC/PEX±IG, ECL‐based combinations demonstrated significant lower mortality unlike RTX‐based combinations. Moreover, when mortality rates were analyzed separately by whether or not the combinations included PEX, IG, or GC, only those that included PEX had a significant lower mortality. However, PEX did not have an impact on mortality in combinations that included RTX and/or ECL.

**Conclusions :**Our analysis indicates improved CAPS mortality rates when ECL and RTX are incorporated early in the treatment regimen. We recommend a paradigm shift in CAPS frontline treatment which should consist of AC+GC+ECL+RTX+ therapies targeting the underlying medical condition. Time is of the essence, and highly active agents should be used upfront in CAPS to significantly lower mortality and morbidity.
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**Background :**Antiplatelet drugs targeting G‐protein coupled receptors (GPCR) are currently used for the secondary prevention of atherothrombotic events. A general limitation of these drugs is that they increase the bleeding risk. First clinical studies suggest that the targeting of ITAM‐linked receptors such as glycoprotein VI (GPVI) provide a better antithrombotic‐haemostatic profile. This urges for high‐throughput assays to screen for potential inhibitory drugs of the latter receptor pathways.

**Aims :**To develop a high‐throughput screening assay for finding new inhibitory molecules that differentiate between ITAM‐linked receptor and GPCR‐induced platelet activation.

**Methods :**Washed human platelets were loaded with Calcium‐6 dye and activated with collagen‐related peptide (CRP) or thrombin in 96‐ or 1536‐well plates by automated pipetting by Flex Station‐3 or FLIPR‐Tetra robots, respectively. Using a panel of 25 known antiplatelet agents, each inhibiting specific signalling steps (receptors, phospholipases, protein kinases, Ca^2+^‐ATPases), we developed an algorithm to identify drugs that maximally differentiate in the suppression of GPVI‐ and PAR1/4‐responses. This information was used for the evaluation of a 10,000 small molecule compound screen in 1536‐well plates.

**Results :**Both in 96‐ and 1536‐well plates, the GPVI agonist CRP showed time‐prolonged \[Ca^2+^\]i increases, whereas the PAR1/4 agonist thrombin evoked quick monophasic transient \[Ca^2+^\]i rises. The activation profile was described using three curve parameters: area under the curve, calcium increase, and slope. Most panel antagonists differed in their effects on CRP‐ or thrombin‐induced parameters. Pathway analysis revealed separate signalling domains, (in)directly downstream of ITAM‐linked or G‐protein coupled receptors. The separate mode of inhibition in response to CRP or thrombin was confirmed by a screening of 10,000 publicly available small molecule compounds. Discriminative molecules, not affecting cell viability, were selected for further analysis.

**Conclusions :**Ultra high‐throughput screening assay of agonist‐induced \[Ca^2+^\]i rises has the potential to identify new antiplatelet drugs with a discriminative mode of receptor‐dependent action.
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**Background :**Primary immune thrombocytopenia (ITP) is an acquired autoimmune disease characterized by isolated thrombocytopenia. A growing body of emerging evidence indicates that abnormalities during any stage of thrombopoiesis and megakaryocytopoiesis can influence platelet production.

**Aims :**Our study tried to find the abnormalities of hematopoietic stem and progenitor cells (HSPCs) in ITP patients from the perspective of single cell transcriptome.

**Methods :**CD34^+^ HSPCs were isolated from BM of four newly diagnosed ITP patients and 2 healthy adults as controls by fluorescence‐activated cell sorter (FACS), and Single‐cell RNA sequencing (scRNA‐seq) data was collected using the recommended protocol for the 3' scRNA‐seq 10× genomics platform.

**Results :**We perform scRNA‐seq for 50,375 single CD34^+^ HSPCs, and detected over 3,000 expressed genes per cell on average. We visualized the cells in 2D space using t‐distributed stochastic neighbor embedding (tSNE) (Fig 1. a and Fig 1. c). Heatmap showed the scaled expression of top 10 differentially expressed genes in each cluster (Fig 1. b). Cell clusters expressed established markers of hematopoietic populations, revealed diverse hematopoietic cell types and implied differentiation trajectories consistent with current views of hematopoiesis. We identified an unambiguous feature of HSPCs in ITP patients with the up‐regulation of the metallothionein family genes (MT2A, MT1G, MT1X, MT1E and MT1F), which was most pronounced in megakaryocyte erythroid progenitor (Fig 1d). Metallothioneins (MTs), encoded by these genes, exhibit significant chelating properties and play a key role in trace elements homeostasis, protection against oxidative stress, and toxic heavy metals. Our study suggested that the metallothionein family genes were involved in the pathogenesis of ITP.

**Conclusions :**Using scRNA‐seq, we revealed a hierarchically‐structured transcriptional landscape of hematopoietic differentiation of BM CD34 + HSPCs. We observed a significantly increased expression of the metallothionein family genes in newly diagnosed ITP patients, which might relate with the generation of abnormal MKs and be a biomarker potentially using in diagnosis.

**Figure 1** ScRNA‐seq analysis of the BM HSPCs from ITP patients and controls
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**Background :**Structural variants (SVs) are genomic rearrangements affecting \> 50 bp and are a major source of variation in the human genome. In antithrombin deficiency (ATD) MLPA detects SVs in \> 8% of cases, but this method doesn′t inform about the genetic architecture nor the exact sequence at the breakpoints. These limitations can be addressed by combining multiple sequencing technologies, including long‐read sequencing.

**Aims :**To characterize SVs affecting *SERPINC1* in the largest ATD series described so far.

**Methods :**Eighteen patients with ATD caused by SVs detected by MLPA were further studied by Long Range‐PCR (LR‐PCR), NGS (Illumina), CGH array (CGHa) (CytoScan^®^ HD) and/or nanopore sequencing (Oxford Nanopore Technologies, ONT).

**Results :**Seven patients carried whole gene deletions, eight partial deletions and three partial duplications. LR‐PCR of small SVs detected the breakpoint in five cases, all involving repetitive elements (RE). CGHa only detected big SVs (\>50 kb), but defined the length (2--76 genes) and supported RE (SINEs and LINEs) at the breakpoint junctions. ONT was used to characterize the genetic architecture of eight SVs. RE and microhomologies were identified for all the cases. Interestingly, this method resolved the first complex SV (cxSV) in one case with normal CGHa, deletion of exon 1 according to MLPA and deletion of exon 1--2 by LR‐PCR. ONT showed a final *SERPINC1* architecture explained by a duplication of exon 2--3, and posterior deletion of exon 1--2, with two breakpoints implying RE

**Conclusions :**The study of the largest cohort of SVs in patients with ATD shows a wide heterogeneity in size (193 bp--8 Mb) and type of SVs (deletions, duplications and a cxSV) (Table 1). We suggest that ONT is the most suitable method to characterize SVs associated with ATD. The high frequency of RE and SVs surrounding *SERPINC1* also suggest this gene is a hot‐spot for genetic rearrangements.PI18/00598 (ISCIII&FEDER); 19873/GERM/15 (Fundación Séneca).

**Table 1**  Characteristics of the 18 cases with antithrombin deficiency caused by structural variants and evaluated by different methods
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**Background :**Intravenous injection of thrombolytic agents, such as tissue plasminogen activator (tPa), can be used to enzymatically breakdown the blood clot to re‐establish blood flow through the affected vessel. However the use of thrombolysis is currently limited by its short time window of efficacy, and the risk of life‐threatening haemorrhage. Iron oxide nanoparticles (IONPs) can be heated by exposure to an external alternating magnetic field. These IONPs can be conjugated with peptides and antibodies to allow their targeting to blood clots.

**Aims :**To investigate whether magnetic hyperthermia (MH) induced by platelet‐targeted IONPs (P‐IONPs) could be used to enhance the efficacy of tPa‐mediated thrombolysis.

**Methods :**PAC‐1 antibody was conjugated to citrate‐coated IONP to generate platelet‐targeted magnetic nanoparticles. *Ex vivo* generated human blood clots and 3D HUVEC cell cultures were incubated with the P‐IONPs and then exposed to tPa in the presence or absence of magnetic stimulation. Clot structure and permeability were assessed by confocal and electron microscopy. ANOVA and Student\'s t‐test were used to assess statistical significance.

**Results :**MH induced by P‐IONPs was found to increase the permeability of blood clots to 70 kDa fluorescent dextran (138 ± 17% of control, n = 10, *P* \< 0.05). MH enhanced the thrombolytic activity of tPa -- reducing the weight of tPa + MH treated clots to 75.6 ± 1.5 % of untreated control clots, compared to 81.3 ± 2.2% of control in clots treated with tPa alone (n = 15, *P* \< 0.05). Using electron microscopy, MH was observed to enhance tPa‐mediated clot disruption. There was no observable increase in cell death of HUVEC cell cultures exposed to P‐IONP‐mediated MH.

**Conclusions :**Platelet‐targeted magnetic nanoparticles could act as an adjuvant to enhance the efficacy of current thrombolytic therapies through the induction of localised MH.

Supported by the Wellcome Trust (207617/Z/17/Z).
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**Background :**Nowadays little is known about the molecular profile of the occluding thrombus and its relationship with its origin and clinical evolution of patients with ischemic stroke (IS).

**Aims :**To analyze the proteomic profile of thrombi obtained by thrombectomy in IS patients, its association with the presence of specific CV risk factors, and the clinical evolution after thrombectomy.

**Methods :**Fifty thrombi of stroke patients with embolic or atherothrombotic origin obtained by thrombectomy were analyzed by SWATH‐MS. Besides, parameters associated with increased risk of stroke were evaluated. Likewise, neurological function (NIHSS) and cerebral involvement (ASPECTS) prior to thrombectomy and the clinical status of patients at 3 months of IS were evaluated, using the modified Rankin scale (mRS).

**Results :**Proteomic analysis allowed the identification and quantification of 585 proteins, mainly related to primary hemostasis, integrin and kinase signaling linked to integrins, glycolysis and acute phase reactants. Comparative analyses identified four protein signatures based on predisposing factors such as hypertension, dyslipidemia, obesity and diabetics. Likewise, 15 proteins, related to immune response or cellular metabolism and involved in vascular diseases, correlated with the NIHSS and ASPECTS scales.

Interestingly, 10 altered proteins in patients with negative evolution at 3 months (mRS \> 2) were identified, associated with the development of stroke or brain damage, platelet aggregation, mortality and arterial thrombosis. Among them, gelsolin (GSN) and Integrin‐linked kinase (ILK) were found increased in the serum of patients with mRS \> 2 at 3 months, suggesting that they could be considered circulating biomarkers of negative clinical evolution.

**Conclusions :**The use of the SWATH‐MS technique has allowed the identification of numerous proteins in the thrombi and the characterization of protein signatures as potential biomarkers to determine their origin and define a therapeutic strategy after IS.

Supported by Junta de Andalucía (PAIDI CTS620).
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**Background :**Development of alloantibodies against factor VIII (FVIII) is a major complication of replacement therapy in sever hemophilia A patients. However, absence of endogenous FVIII does not necessarily lead to the incidence of inhibitors. The maternal cells migrate into fetus tissue during pregnancy and stays beyond birth. Unlike cells harboring F8 mutations in host hemophilia A fetus, maternal chimeric cells are able to express FVIII albeit at low level, we thus speculate whether the maternal chimeric cells could induce tolerance toward FVIII and prevent development of inhibitors.

**Aims :**To investigate the association of maternal chimerism and development of factor VIII inhibitors in hemophilia A patients.

**Methods :**The study recruited 83 hemophilia A patient‐mother pairs, including 25 patients with inhibitors. All patients presented sever deficiencies of FVIII caused by intron 22 inversions, large deletions, nonsense or frame shift mutations, and had been exposed to both plasma‐derived and recombinant FVIII in replacement therapy. Three SNPs on X chromosome with high minor allele frequency (MAF) in Chinese were selected as marker for individual DNA identification. The degree of maternal chimerism was examined by droplet digital PCR. Multivariable logistic regression was conducted to test associations between presence of maternal chimerism and the development of inhibitors.

**Results :**Among 20 patients with SNP allele representing of maternal origin presented, only 2 (10%) had inhibitors developed, while in 63 patients who failed to have maternal SNP alleles detected, 23 (34.3%) were inhibitor positive (odds ratio: 5.18, 95% CI:1.10‐ 24.34) (*P* = 0.037).

**Conclusions :**Maternal chimeric cell may have induced immune tolerance in hemophilia A patients and absence of maternal chimeric cell constitutes a risk factor for inhibitor development.
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**Background :**Hereditary hemorrhagic telangiectasia (HHT, Osler‐Weber‐Rendu disease) is a rare bleeding disorder causing chronic gastrointestinal bleeding, epistaxis, and severe anemia. Bevacizumab, an anti‐vascular endothelial growth factor antibody, may be effective to treat bleeding in HHT. Current data evaluating this is limited to small single‐center case series.

**Aims :**Evaluate safety and effectiveness of systemic bevacizumab to treat HHT‐associated bleeding in a large, multicenter, international study.

**Methods :**Multicenter retrospective study of HHT patients receiving bevacizumab at 12 international HHT treatment centers, comparing hemoglobin, epistaxis severity score (a well‐validated 10‐point bleeding score in HHT), RBC transfusions, and iron infusions before and after bevacizumab treatment.

**Results :**238 patients were treated with bevacizumab for a median of 12 (range, 1--96) months. Compared with pretreatment, bevacizumab increased mean hemoglobin by 3.2 g/dL (95% CI, 2.9--3.5 g/dL) \[mean hemoglobin 8.6 (8.5--8.8) g/dL versus 11.8 (11.5--12.1) g/dL, *P* \< 0.0001)\] and decreased the epistaxis severity score (ESS) by 3.4 (3.2--3.7) points \[mean ESS 6.8 (6.6--7.1) versus 3.4 (3.2--3.7), *P *\<* *0.0001\] during the first year of treatment, Figure 1A,B. Compared with 6 months pretreatment, RBC units transfused decreased by 82% \[median of 9.0 (IQR 5.0--16.0) units versus 0 (IQR, 0.0--2.0) units, *P *\<* *0.0001\] and iron infusions decreased by 70% \[median of 8.0 (3.0--20.0) infusions versus 2.0 (0.0--5.0) infusions, *P *\<* *0.0001\] during the first 6 months of bevacizumab treatment, Figure 1C,D. Outcomes were similar regardless of underlying pathogenic mutation. Following initial induction infusions, continuous/scheduled bevacizumab maintenance achieved higher hemoglobin and lower ESS than intermittent/as needed maintenance but with more drug exposure. Bevacizumab was well tolerated, with 343 patient‐years of treatment evaluable for adverse events; hypertension, fatigue, proteinuria, and myalgia/arthralgia were most common (TABLE) and 5% of patients discontinued treatment due to side‐effects.

**Conclusions :**In a large. multicenter, international study, systemic bevacizumab was safe and highly effective to manage chronic bleeding and anemia in HHT.

**Figure 1** Box‐and‐whisker plots showing effect of intravenous bevacizumab on outcome measures. Mo, months; PreTx, pretreatment; On Tx, on treatment

**Table 1** Treatment‐emergent adverse events (TEAEs) identified by treating clinician as likely or possibly due to bevacizumabTreatment‐Emergent Adverse EventNumber of Patients (%)Treatment‐Emergent Adverse EventNumber of Patients (%)Hypertension (new‐onset or worse from baseline)41 (18%)\*Rash3 (1%)Fatigue23 (10%)Abdominal pain/gastrointestinal upset3 (1%)Proteinuria21 (9%)Lightheadedness2 (1%)Myalgia and/or arthralgia14 (6%)Dyspnea2 (1%)Headache9 (4%)Hoarseness2 (1%)Venous thromboembolism5 (2%)Bone marrow suppression2 (1%)Transaminase/alkaline phosphatase elevation3 (1%)Other\*\*7 (3%)

\*26 patients with new‐onset hypertension and 15 patients with hypertension worsened from baseline.

\*\*Includes one report each of lower extremity edema, worsened epistaxis, diarrhea, lower extremity venous ulceration, poor wound healing, non‐cardioembolic stroke, and Staphylococcus aureus skin infection.
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**Background :**HA, a congenital bleeding disorder caused by a deficiency in clotting factor (F)VIII, is characterized by uncontrolled bleeding and musculoskeletal dysfunction. Little research has been conducted on the clinical burden across disease severity, especially in mild and moderate HA.

**Aims :**To examine clinical outcomes by disease severity in adult persons with HA (PwHA) without current FVIII inhibitors.

**Methods :**CHESS II (Cost of Haemophilia in Europe: a Socioeconomic Survey‐II) is a retrospective, burden‐of‐illness study in adults with mild, moderate, and severe hemophilia (defined by endogenous FVIII/IX \[IU/dL\]) across 8 European countries. Data on clinical outcomes and healthcare resource utilization were captured via electronic case record forms disseminated to hemophilia specialists. Overall, 12 months' retrospective data on bleeding episodes and joint outcomes were examined. Informed consent was obtained and the study was approved by the University of Chester ethical committee.

**Results :**Bleed data were available for 580/601 PwHA without current FVIII inhibitors. Mean age and body mass index were similar across severity groups (Table 1). Only 9% and 2% of persons with moderate and mild HA, respectively, received prophylaxis. In moderate HA, mean annual bleed rate (ABR) was 3.06 (standard deviation \[SD\], 7.5); marginally different to in severe HA (mean \[SD\], 3.91 \[6.4\]). In moderate HA, 15% had zero bleeds in the past year, 39% had problem joints (i.e., chronically damaged joints), and 24% had joint surgery. In mild HA, mean ABR (SD) was 2.12 (10.1). Notably, only 26% of persons with mild HA had zero bleeds in the past year, 17% had problem joints and 7% had joint surgery, indicating a potential unmet need in this population (Table 2).

**Conclusions :**Persons with mild and moderate HA appear to exhibit a clinical burden and potential unmet medical need expressed in bleeding frequency, problem joints and incidence of surgeries to affected joints.

**Table 1** Baseline Demographics and CharacteristicsMild HA (n = 97)Moderate HA (n = 199)Severe HA (n = 284)All (N = 580)Mean age (SD), years39.41 (14.8)38.82 (15.1)37.24 (13.8)38.15 (14.4)Mean BMI (SD)24.59 (2.4)24.59 (3.0)24.65 (2.8)24.62 (2.8)Treatment strategy, n (%) No treatment69 (71)120 (60)0189 (33) Primary on‐demand\*26 (27)50 (25)105 (37)181 (31) Primary prophylaxis†0028 (10)28 (5) Secondary on‐demand‡012 (6)23 (8)35 (6) Secondary prophylaxis§2 (2)17 (9)128 (45)147 (25)

\*Primary on‐demand: treatment has always been episodic or 'on‐demand'.

^†^Primary prophylaxis: treatment has always been prophylactic.

^‡^Secondary on‐demand: previously on prophylaxis, currently receiving treatment episodically or 'on‐demand'.

^§^Secondary prophylaxis: treatment was previously episodic or 'on‐demand', currently on prophylaxis.

BMI, body mass index; HA, hemophilia A; SD, standard deviation.

**Table 2** The Frequency of Bleeds and Joint Damage in Persons with Mild, Moderate, and Severe HAMild HA (n = 97)Moderate HA (n = 199)Severe HA (n = 284)All (N = 580)Mean annual bleed rate (SD)2.12 (10.1)3.06 (7.5)3.91 (6.4)3.32 (7.5)Zero bleeds, n (%)25 (26)29 (15)21 (8)75 (13)1 bleed, n (%)44 (45)57 (29)51 (18)152 (26)≥2 bleeds, n (%)28 (29)113 (57)212 (75)353 (61)Target joint, n (%)8 (8)46 (23)128 (45)182 (31)Problem joint, n (%)17 (17)77 (39)138 (49)232 (40)Joint surgery\*, n (%)7 (7)48 (24)73 (26)128 (22)

\*Target joint surgery includes: arthrocentesis (joint aspiration), arthrodesis (joint fusion), arthroplasty (joint reconstruction/replacement), arthroscopy (joint examination/repair via endoscope), and synovectomy (removal of synovium).

HA, hemophilia A; SD, standard deviation.
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**Background :**BAY 2599023 (AAVhu37.hFVIIIco) comprises an adeno‐associated virus vector with capsid serotype hu37 (AAVhu37), and a genome that directs expression of a codon‐optimized B‐domain‐deleted human factor VIII (hFVIIIco) under the control of a liver‐specific promoter/enhancer combination.

**Aims :**We report safety and FVIII activity in this first‐in‐human study.

**Methods :**This phase 1/2, open‐label, dose‐finding study (NCT03588299) included male patients aged ≥ 18 with severe hemophilia A, receiving a single intravenous infusion of BAY 2599023. Patients had no history of FVIII inhibitors, no detectable immunity to the AAVhu37 capsid and \> 150 exposure days to FVIII products. Primary endpoints were adverse events (AEs), serious AEs (SAEs) and AEs/SAEs of special interest (S/AESIs). Secondary endpoint was change in FVIII activity from baseline. Informed patient consent and ethics committee approval were obtained.

**Results :**Three cohorts of two patients were enrolled sequentially. Following 52 weeks of safety observation of the first cohort (0.5 × 10^13^ GC/kg), no SAEs, study‐drug‐related AEs or S/AESIs were reported. Despite the low dose, clear evidence of FVIII coagulant activity was observed (˜5‐ 20%). One patient was off prophylaxis for ˜7 months. After ˜28 weeks of follow‐up of the second cohort (1.0 × 10^13^ GC/kg), both patients have FVIII activity (˜8‐ 40%) and are off prophylaxis. One AESI, mild elevation in alanine aminotransferase/aspartate aminotransferase, was recorded (responded to short corticosteroid treatment without loss of FVIII activity). Following safety review, escalation to 2.0 × 10^13^ GC/kg was recommended. Currently, two patients have been treated for ˜10 weeks and off prophylaxis for ˜4 weeks. AESIs of mild‐to‐moderate elevation in alanine aminotransferase/aspartate aminotransferase were recorded for both patients (responded to corticosteroid treatment).

**Conclusions :**Six patients were treated with BAY 2599023 at doses of 0.5, 1.0 and 2.0 × 10^13^ GC/kg. Successful proof‐of‐concept has been achieved with measurable, stable expression of endogenous FVIII and indications of hemostatic efficacy in all treated patients.
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**Background :**Current Factor VIII (FVIII) replacement therapies still have several limitations such as a short plasma half‐life, the lack of subcutaneous bioavailability, and a high immunogenic potential resulting in the development of inhibitory antibodies or precluding the subcutaneous administration route.

**Aims :**The development of novel recombinant FVIII molecules addressing all major limitations of current FVIII substitution therapy.

**Methods :**Biotest\'s Hemophilia A Therapeutic (HAT) molecule was generated by introducing four albumin‐binding domains into a single chain FVIII sequence. In parallel, 19 deimmunizing mutations were incorporated into the FVIII sequence of HAT resulting in HAT RI (Reduced Immunogenicity). Both molecules were produced in a human cell line, purified and extensively tested *in vitro*. Half‐life extension was investigated after *i.v*. injection in hemophilia A mice, Göttingen minipigs and albumin‐deficient mice expressing the human FcRn a‐chain. Subcutaneous administration was tested in hemophilia A mice and Göttingen minipigs. A tail transection assay in hemophilia A mice was used to determine *in vivo* functionality. As FVIII‐bound albumin may shield HAT and HAT RI from present FVIII inhibitors, the bypassing activity of both molecules was assessed by a modified Bethesda assay. Additionally, immunological aspects were investigated by LC‐MS to identify MHC II‐presented peptides of HAT RI on dendritic cells.

**Results :**Both FVIII molecules HAT and HAT RI demonstrated full *in vitro* and *in vivo* functionality while providing up to a 4‐fold longer half‐life compared to Moroctocog alfa in the albumin‐deficient mouse model. Subcutaneous administration resulted in up to 50% bioavailability in the minipig model. Bypassing activity in the presence of inhibitors was observed in combination with reduced MHC II‐presentation showing improved immunological compatibility.

**Conclusions :**HAT and HAT RI address the major challenges of FVIII substitution therapy as both molecules have a superior half‐life, show high subcutaneous bioavailability in mice and pig models, and reduce FVIII immunogenicity according to utilized *in vitro* models.
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**Background :**Pulmonary vascular obstruction, measured by the pulmonary vascular obstruction index (PVOI), has been associated with an increased risk of venous thromboembolism (VTE) recurrence. But results are not entirely consistent, and PVOI classification cut‐offs vary among studies.

**Aims :**The primary objective of this work is to assess if elevated PVOI is an independent risk factor of VTE recurrence after a first PE episode, and to estimate which PVOI cut‐off values would be the most discriminating for predicting VTE recurrence.

**Methods :**We pooled individual data from 3 studies within the F‐CRIN INNOVTE network: a randomized clinical trial and two cohort studies. PVOI was measured in percentage by ventilation/perfusion lung scan at the time of index PE (initial PVOI), and after initial anticoagulation therapy (residual PVOI). VTE recurrence was defined as objectively confirmed PE or deep vein thrombosis. Associations between PVOI (initial and residual) and VTE recurrence were jointly estimated using a multivariate Cox proportional hazards regression model. To manage confounding, the model was further stratified on the study, and adjusted on anticoagulant therapy duration. Optimal PVOI thresholds were estimated by 10‐fold cross‐validation, using areas under curve (AUC) computed from time‐dependant receiver‐operating characteristic (ROC) curves.

**Results :**The total number of patients was 922. Median duration of follow‐up was 42 months (IQR: 38--60). VTE recurrence occurred in 149 patients (4.2 events per 100 person‐years). Most discriminating cut‐offs were initial PVOI \> 35% (AUC: 0.71, CI95%: 0.71--0.71), and residual PVOI \> 5% (AUC: 0.69, CI95%: 0.68--0.69). Initial PVOI \> 35% and residual PVOI \> 5% were significantly associated with the risk of VTE recurrence (HR: 1.61, CI95% 1.07--2.43 and HR: 1.63, CI: 95%: 1.06--2.50, respectively).

**Conclusions :**After a first PE episode, initial PVOI \> 35% and residual PVOI \> 5% were found to be independent predictors of VTE recurrence. In the future, those results could help detect more accurately patients with high risk of VTE recurrence.
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**Background :**Cancer‐associated venous thromboembolism (VTE) risk prediction scores perform poorly in non‐small cell lung cancer (NSCLC), possibly because tumor molecular subtype is omitted. Prior studies suggest a possible increased VTE risk in *ALK*‐rearranged NSCLC, but data are conflicting.

**Aims :**Evaluate venous and arterial thrombotic risk conferred by the ALK rearrangement in NSCLC.

**Methods :**Retrospective cohort study of advanced‐stage NSCLC patients diagnosed between 2009 and 2019. Multivariable time‐to‐event analyses modeling thrombotic risk in *ALK* and non‐*ALK* NSCLC groups controlling for covariates impacting thrombosis risk (15 in VTE model and 17 in arterial thrombosis model) were performed using Cox proportional hazards regression and competing‐risks regression (with death as the competing risk). Multivariable negative binomial regression modeled total VTE rate.

**Results :**422 *ALK*‐rearranged and 385 non‐*ALK*‐rearranged NSCLC patients were included. *ALK* patients were younger (mean age 50 vs. 66 years, *P *\<* *0.001, TABLE), had better performance status and significantly lower rates of most VTE risk factors but had significantly higher rates of initial VTE (42.7% vs. 28.6%, FIGURE) and recurrent VTE (13.5% vs. 3.1%) than non‐*ALK* NSCLC. VTE risk attributable to *ALK* was significant

\[Cox model: HR 3.70 (95% CI, 2.51--5.44, *P *\<* *0.001); competing‐risks: SHR 3.91 (95% CI, 2.55--5.99, *P *\<* *0.001)\]. Negative binomial modeling demonstrated higher VTE rates in *ALK* patients \[IRR 2.47 (95% CI, 1.72--3.55, *P *\<* *0.001)\]. OR for recurrent VTE was 4.85 (95% CI, 2.60 to 9.52, *P *\<* *0.001). Despite significantly lower rates of all major arterial thrombosis risk factors, arterial thrombosis rates were similar (5.0% vs. 4.4%). Arterial thrombosis risk attributable to *ALK* was significant \[Cox model: HR 3.15 (95% CI, 1.18--8.37, *P = *0.021); competing‐risks: SHR 2.80 (95% CI, 1.06--7.43, *P = *0.038)\].

**Conclusions :**In time‐to‐event analyses controlling for thrombosis risk factors, the *ALK* rearrangement conferred a 4‐fold increase in VTE risk and 3‐fold increase in arterial thrombosis risk in NSCLC. These patients may benefit from pharmacologic thromboprophylaxis.

**Table 1** Patient characteristics of ALK and non‐ALK groupsCharacteristicALK‐rearranged NSCLCControl (Non‐ALK) NSCLC*P* value*Covariates included in VTE risk models:*ALK status, sex, age, BMI, histology, smoking status, ECOG performance status, Khorana Risk Score, known thrombophilia, prior VTE, brain metastases, receipt of thrombogenic chemotherapy, surgery 90 days prior to VTE, systemic inflammatory disorder, receipt of tyrosine kinase inhibitors, and pre‐existing indefinite anticoagulationAge (years), mean (range)50 (18--86)66 (29--92)\<0.0001*Covariates included in arterial thrombosis risk models:*ALK status, sex, age, BMI, race, ethnicity, smoking status, ECOG performance status, Khorana Risk Score, hypertension, diabetes mellitus, hyperlipidemia, atherosclerosis, atrial fibrillation, heart failure, obstructive sleep apnea, baseline creatinine, and receipt of tyrosine kinase inhibitors% Female53580.14Median time at risk (from diagnosis to death or last follow‐up)944 days733 days\<0.0001ECOG performance status, mean0.761.48\<0.0001Khorana risk score at diagnosis, mean1.411.430.76Smoking status, % Current or Former Smoker29.9%77.1%\<0.0001Venous thromboembolism, N (%)180 (47.2%)110 (28.6%)\<0.0001Recurrent VTE, N (%)57 (13.5%)12 (3.1%)\<0.0001Arterial thrombosis, N (%)21 (5.0%)17 (4.4%)0.71

**Figure 1** Kaplan‐Meier curves demonstrating VTE‐free survival in each group. Black hashes are censor events due to death or loss to follow‐up
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**Background :**The current diagnostic delay of chronic thromboembolic pulmonary hypertension (CTEPH) after acute pulmonary embolism (PE) is unacceptably long exceeding 1 year, causing loss of quality‐adjusted life years and excess mortality. Validated screening strategies to diagnose CTEPH earlier are lacking. Importantly, performing echocardiography in all PE patients for this purpose has a low diagnostic yield, is associated with overdiagnosis and is not cost‐effective. Moreover, expertise in performing high‐quality PH‐dedicated echocardiograms may not be available outside expert centers.

**Aims :**To validate a simple screening strategy aimed at identifying CTEPH early in the course after acute PE, avoiding echocardiography if possible (Figure 1).

**Methods :**In this prospective, international, multicenter management study, consecutive PE survivors were managed according to the predefined algorithm starting three months after acute PE. All were followed for a total period of two years. The study protocol was approved by all local IRBs and all patients provided informed consent.

**Results :**424 patients were included across three European countries (Table 1). Following the algorithm, CTEPH was considered excluded in 343 (81%) patients based on clinical pre‐test probability assessment by the 'CTEPH prediction score', evaluation of symptoms and application of the 'CTEPH rule‐out criteria' (Figure 1); only 19% was subjected to echocardiography. One of 343 patients managed without echocardiography was diagnosed with CTEPH, 10 months after initial PE, for a failure rate of 0.29% (95% CI: 0--1.6%). Overall, 13 patients were diagnosed with CTEPH (incidence 3.1%), of whom 10 within 4 months after PE diagnosis.

**Conclusions :**The algorithm accurately ruled out CTEPH and avoided echocardiography in 81% of patients. The vast majority of CTEPH cases were identified early in the course of acute PE which is a considerable improvement compared to current clinical practice with an economic use of healthcare resources.

**Table 1** Baseline characteristics of patients included in the InShape II study

**FIGURE 1** CTEPH screening algorithm applied 3 months after diagnosis, and results of 2‐year follow‐up
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**Background :**Cancer‐associated venous thromboembolism (CAT) remains one of the leading causes of morbidity and mortality in cancer patients. Specific biological targets for cancer individuals at risk for venous thromboembolism (VTE) are presently missing.

**Aims :**The aims of this study are to explore the protein signature in CAT compared to non‐cancer VTE and to investigate the relation of cancer‐related proteins with clinical outcome e.g. recurrent VTE and/or bleeding.

**Methods :**A total of 652 individuals with acute VTE from the Genotyping and Molecular Phenotyping of Venous ThromboEmbolism (GMP‐VTE) Project, of which 82 subjects had cancer, were included in this analysis. The proteomic profile was investigated in EDTA plasma with proximity extension assay technology (Olink Biosciences, Uppsala, Sweden). Quantification of 444 unique proteins from Cardiovascular, Cardiometabolic, Inflammation and Immune Response panels were used for analysis. Least absolute shrinkage and selection operator (LASSO)‐regularized logistic regression, adjusted for age, sex, clinical profile and therapy was used to identify most relevant proteins associated with CAT. Age and sex adjusted Cox regression with competing risks (mortality) established the link of the CAT‐related proteins to clinical outcome.

**Results :**LASSO regression identified 69 variables (n = 60 were unique proteins) with an area under the curve (AUC) of 0.89 (10‐fold cross‐validated AUC: 0.66) for differentiating CAT from non‐cancer VTE. The identified proteins were primarily related to the immune response including interleukin and cytokine signaling, angiogenesis, cell growth regulation, complement and coagulation pathways. Monocyte chemoattractant protein (MCP)‐1 was associated with less recurrent VTE in cancer subjects with HR = 0.46 (0.29--0.72), *P* = 0.0007. Additionally, transcription regulator protein BACH‐1 was linked to less incident bleeding in cancer (HR = 0.56 \[0.41--0.76\], *P* = 0.0003).

**Conclusions :**CAT subjects presented with different humoral proteomic patterns compared to non‐cancer VTE, independent of clinical risk factors and therapy. MCP‐1 and BACH‐1 were linked with better clinical outcome in cancer patients.
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**Background :**Thromboembolic events (TE), both arterial and venous, are the most common complications of myeloproliferative neoplasms (MPN). Clinical parameters such as patient age and mutation‐status are used to risk‐stratify patients but a true biomarker of TE risk in MPN is lacking. Protein disulfide isomerase (PDI) is an endoplasmic reticulum protein vital for protein folding, but also possesses essential extracellular functions, including initiation of thrombus formation. Pharmacologic PDI inhibition prevents TE in cancer but whether pathologic increases in PDI increase TE risk remains unknown.

**Aims :**Evaluate association of plasma PDI levels and risk of TE in MPN.

**Methods :**Patients (established MPN) and controls (non‐MPN hematologic diagnosis without significant kidney, liver or cardiac dysfunction or active cancer) were enrolled. Plasma PDI was measured at enrollment by ELISA and patients followed prospectively for development of TE.

**Results :**A total of 65 MPN patients and 28 controls were enrolled. A subset of patients, primarily JAK2‐mutated MPN, had elevated plasma PDI levels at enrollment (Figure 1A). PDI levels correlated with PDI activity determined by a functional assay (R^2^=0.6). No correlation between age, blood counts/hematocrit, plasma platelet factor 4, or cytoreductive therapy and PDI levels was notable. The cumulative incidence of TE in the MPN cohort was 11.4% per year. A receiver operating characteristic (ROC) analysis of PDI levels in patients who developed TE was performed to identify cutoff predictive of TE. Accordingly, the risk of TE in patients with PDI \> 10.9 ng/mL was 8‐fold greater than PDI \< 10.9 ng/mL (HR 8.0 (2--32.2); *P* = 0.013). Adding plasma PDI levels in patients with high‐risk MPN (IPSET scores \> 3; n = 46) improved the specificity of IPSET scoring to predict TE (HR 6.9 (1.6--30.4), *P* = 0.036, versus HR 3.5 (0.8--15.1), *P* = 0.22).

**Conclusions :**Pathologic increases in PDI in patients with MPN was predictive of an increased risk of thromboembolic events.

**Figure 1** Elevated plasma PDI in MPN A) A population of MPN patients have elevated plasma PDI. B) Plasma PDI \> 10.9 ng/mL predict the development of TE in MPN
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**Background :**Exposure of pregnant women to vitamin‐K antagonists (VKA) carries a high risk for embroypathy (at least 7%), but for direct oral anticoagulants (DOAC) the embryopathy risk is still unknown.

**Aims :**We aimed to evaluate pregnancy outcomes after DOAC exposure using data from various sources.

**Methods :**Cases of DOAC pregnancy exposure were collected from literature search, from questionnaires sent to German gynecologists, obstetricians and hematologists and from pharmacovigilance databases with the DOAC manufacturers, the German drug authority (BfArM) and the European Medicines Agencies (EMA).

**Results :**A total of 1084 exposure reports were identified and, after removing duplicates, 588 (likely separate) cases of DOAC exposure in pregnancy could be identified. A main limitation was the lack of details and insufficient follow‐up data in the datasets provided by DOAC manufacturers and authorities.

Information of pregnancy outcome was available in 313/588 cases (53.2%; Figure 1) and consisted of 172 live births (55.0%); 69 miscarriages (22.0%); 72 elective pregnancy interruptions (23.0%). In 1 case, the pregnancy was still ongoing. In 273 cases (46.4%) no outcome data were available.

In the 313 pregnancies with reported outcomes 19 abnormalities were reported (6.1%) of which 12 could potentially be related to DOAC exposure (Figure 1; highlighted in red bold italic), which would translate into an overall embryopathy risk of 3.8%. Within the 172 live births, abnormalities occurred in 12 cases and 9 were rated as potential embryotoxicity (5.2%).

**Conclusions :**Currently available data suggest that the risk for DOAC embryopathy is lower than that reported for VKA exposure. Still, despite increasing case numbers, pregnancy outcomes are insufficiently reported and significant data gaps remain. Pregnancy has to be consequently avoided in DOAC patients, but available data do not justify pregnancy termination based on DOAC exposure alone. Instead, non‐directive counselling, close pregnancy surveillance and outcome reporting to pharmacovigilance is recommended.
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**Background :**Guidelines for postpartum thromboprophylaxis are mostly expert‐based and appear to differ widely. A decision analytic model suggests that a postpartum venous thromboembolism (VTE) risk ≥ 0.2% is an acceptable threshold to justify thromboprophylaxis, but the risk thresholds defined by current guidelines are unclear.

**Aims :**To compare the proportion of women at high risk (with recommended thromboprophylaxis) according to the RCOG, ACOG and ACCP guidelines, and to estimate their absolute risk of VTE.

**Methods :**Among all women who delivered at the Geneva University Hospitals in 01.2019, we collected relevant maternal, obstetrical and fetal characteristics through medical chart review. We determined for each woman the recommended strategy of thromboprophylaxis according to the 3 guidelines. We estimated individual absolute VTE risks using a validated risk prediction model (Sultan, BMJ 2016). Proportions of recommended thromboprophylaxis were compared using proportion tests and risks of VTE using Wilcoxon rank‐sum tests. The local ethics committee approved the study.

**Results :**Among 344 consecutive women (mean age of 32.2y (SD 5.3); BMI of 24.0 kg/m^2^ (SD 4.8)), elective and emergency C‐sections (CS) occurred in 9.6% and 13.7%, respectively. The RCOG guideline categorized 40.1% (25.4% of vaginal deliveries (VD), 88.8% of CS) as high‐risk. The ACOG and ACCP guidelines, which focus exclusively on CS, categorized 35.0% and 46.3% of CS as high‐risk, respectively (RCOG vs. ACOG or ACCP *P* \< 0.001; ACCP vs. ACOG *P* = 0.15).

The median estimated risk of VTE were 0.05% (full cohort), 0.04% (VD) and 0.10% (CS). Absolute risks were greater in high‐risk than low‐risk, but the proportion of women with a risk ≥ 0.2% remained small (Table 1).

**Conclusions :**We found wide variations in prevalences of recommended thromboprophylaxis and their risk thresholds. The RCOG guideline recommends using thromboprophylaxis in 4/10 women, but given their 0.1% risk of VTE, their number needed to treat to prevent 1 VTE event may be very high.

**Table 1** Estimated absolute risks of postpartum VTE and proportions of risks ≥ 0.2% according to the classifications of different guidelinesGuidelinesRCOGACOGACCPAll (n = 344)VD (n = 264)CS (n = 80)CS (n = 80)CS (n = 80)TPX not recommended (median, P10‐90)0.04% (0.03--0.07)0.04% (0.03--0.07)0.09% (0.05--0.13)0.09% (0.05--0.18)0.08% (0.05--0.15)TPX recommended (median, P10‐90)0.09% (0.04--0.21)0.08% (0.03--0.17%)0.11% (0.06--0.26%)0.18% (0.08%--0.34%)0.18% (0.09--0.34)*P*‐value\<0.001\<0.0010.09\<0.001\<0.001Risk ≥ 0.2% among TPX not recommended0/206 (0%)0/197 (0%)0/9 (0%)4/52 (7.7%)0/43 (0%)Risk ≥ 0.2% among TPX recommended15/138 (10.9%)3/67 (4.5%)12/71 (16.9%)8/28 (28.6%)12/37 (32.4%)
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**Background :**The peripartum management of women using low‐molecular weight heparin (LMWH) is challenging. For those using prophylactic LMWH therapy there is much uncertainty and lack of consensus, whether scheduled delivery following a minimum of 12 hours off anticoagulation, would affect the chance of having neuraxial analgesia or result in improved maternal outcomes as compared to allowing spontaneous onset of delivery.

**Aims :**To examine the outcomes of planned induction of labor versus spontaneous onset of labor among women using prophylactic‐dose LMWH therapy.

**Methods :**A retrospective cohort study, performed during 2018--2019 at a university hospital.

**Results :**Data from 199 women were analyzed, 121 (60.8%) women underwent planned induction of labor, whereas 78 (39.2%) were admitted following spontaneous onset of labor. Baseline characteristics of women were similar between the groups. The admission‐to‐delivery interval (median 4.7 vs. 29.3 hours), and the time intervals from the last LMWH injection to delivery (25.8 vs. 48.2 hours) and to the first postpartum LMWH injection (41.2 vs. 63.7 hours), were significantly shorter in those who presented with spontaneous onset of labor as compared to planned induction of labor (*P* \< 0.001 for all comparisons). Among those with spontaneous onset of labor, 69 (88.5%) were eligible to receive neuraxial anesthesia, with no difference in relation to parity. Rates of PPH and blood transfusion were similar between the groups. While no thrombotic events were encountered in those with spontaneous onset of labor, four (3.3%) women who delivered following an induction of labor developed a thrombotic event during the postpartum course.

**Conclusions :**Planned induction of labor among women using prophylactic LMWH therapy, was associated with significantly prolonged duration of anticoagulation interruption as compared to those who developed spontaneous onset of labor. Allowing spontaneous onset of labor was associated with comparable rates of bleeding complications, with a low rate of not having access to neuraxial anesthesia.
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**Background :** *Takotsubo syndrome* (TTS) is a reversible form of ventricular dysfunction mimicking many clinical features of acute coronary syndrome (ACS) without coronary artery occlusion. The underlying pathophysiological mechanisms of TTS are not fully understood, as yet, even if a strong association to stressful conditions and secretion of catecholamines has been observed in post‐menopausal women.

**Aims :**In this study we tested the hypotheses that TTS patients display abnormalities in platelet and fibrin clotting function.

**Methods :**Forty‐five age‐matched women with ACS were enrolled at the index event and, after a differential diagnosis, divided in TTS(N = 26;\< 50% stenosis) and with obstructive coronary disease (CAD)(N = 19;≥50% stenosis). After a 6 months follow‐up, platelet aggregation induced by different stimuli was performed in platelet rich plasma. Functional fibrinogen and polymerization of fibrin clot were assessed in plasma by Clauss method and by spectrophotometric analysis, respectively. Twenty‐four healthy post‐menopausal women were recruited as reference group (CTRL). TTS and CAD patients were all on aspirin treatment. The study complies with the Declaration of Helsinki and was approved by the Hospital Institutional Review Board and Ethical Committee. All participants provided written informed consent.

**Results :**Despite aspirin treatment, an enhanced platelet activation was recorded in TTS patients as shown by increased slope aggregation in response to ADP, epinephrine and norepinephrine vs. CAD and CTRL (*P* \< 0.004). In particular, the maximum platelet aggregation induced by both ADP and norepinephrine was higher in TTS than in CAD patients (*P* = 0.04 and *P* = 0.003, respectively).

No significant differences were observed in response to TRAP‐6. TTS patients have both lower functional fibrinogen level and percentage of fiber clot polymerization than CAD patients (*P* \< 0.0001 and *P* \< 0.012, respectively), being however comparable to CTRL.

**Conclusions :**The data here reported show for the first time an increased residual platelet activation in TTS patients, which however is associated with no change in fibrin clotting ability.
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**Background :**NETosis is an innate immune response occurring after infection or inflammation. Dying neutrophils expel decondensed DNA, combined with histones into the extracellular environment in a controlled way. This activates coagulation and fuels the risk of thrombosis. Human pregnancy is associated with a mild pro‐inflammatory state, characterized by circulatory neutrophil activation which is further increased in complicated pregnancies, placenta‐mediated complications being associated with a high risk of thrombosis. This aberrant activation leads to an increased release of nucleosomes in the blood flow.

**Aims :**The initial aim of our study was to quantify histone‐bound nucleosomes in normal pregnancies as opposed to those with placenta‐mediated complicated. We then analyzed the role of histones on the function of extravillous trophoblasts.

**Methods :**Histones circulating in plasma from 50 normal and 35 complicated pregnancies (clinicaltrials.gov identifier: NCT04205383 and IRB CHU de Nîmes n°19.01.04) were quantified by ELISA. Trophoblast migration of the extravillous cell line HTR‐8/SVNeo was analyzed by wound healing assay and their invasive potential by Matrigel‐coated Transwell^®^ experimentation. Apoptosis was characterized by flow cytometry.

**Results :**Circulating nucleosome‐bound histones H3 and H4 were increased in complicated pregnancies. *In vitro*, we observed that free recombinant H2B, H3 and H4 inhibited collective migration, but only H3 also blocked invasion. H3 and H4 also induced apoptosis whereas H2B did not. Finally, the negative effects of H3 on invasion and apoptosis could be restored with enoxaparin, a low molecular weight heparin (LMWH), but not with aspirin.

**Conclusions :**Different circulating histones are increased in complicated pregnancy and this apparently affects migration, invasion and induces apoptosis of extravillous trophoblasts. Histones might be part of the link between the risk of thrombosis and pregnancy complications, and LMWH has an effect on both.
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**Background :**In children, current standard of care (SOC) with heparins or vitamin K antagonists is limited by parenteral administration and frequent monitoring. Dabigatran etexilate (DE) is an effective oral treatment of venous thromboembolism (VTE) in adults.

**Aims :**Evaluate DE efficacy and safety versus SOC, and the appropriateness of a DE dosing algorithm in children aged \< 2 years (yrs) with VTE compared with older children (≥2 yrs‐ \< 18 yrs).

**Methods :**This was a subgroup analysis of the open‐label, randomized, active‐controlled, multi‐centre, phase IIb/III DIVERSITY trial (NCT01895777; consent obtained and ethics committee approved). Children (birth‐ \< 6 months \[\<6 mos\]; ≥6 mos‐\<2 yrs; ≥2 yrs‐ \< 18 yrs) with an objectively confirmed VTE diagnosis and initially treated with unfractionated heparin or low‐molecular‐weight heparin were randomized (2:1) to DE (capsules/pellets/oral suspension, using an age‐ and body weight‐adjusted dosing algorithm) or SOC, and treated up to 3 months. Primary efficacy endpoint: VTE recurrence, VTE‐related death, and complete thrombus resolution. Safety endpoints: bleeding events (BEs) and adverse events (AEs).

**Results :**Of 267 children in the randomized set, 35 were \< 2 yrs (22 received DE, 13 SOC; 14 were \< 6 mos \[11 DE, 3 SOC\]) and 232 were ≥ 2 yrs‐ \< 18 yrs (155 DE, 77 SOC). Across all age groups (Table), DE was as effective as SOC for the combined efficacy endpoint, and the frequency of major BEs with DE and SOC was similar. The frequency of minor BEs was higher with DE in children \< 2 years (event numbers were low in the two youngest age groups); in those ≥ 2 years‐ \< 18 years, fewer BEs were observed with DE versus SOC. The frequency of serious AEs was comparable for DE versus SOC across all age groups.

**Conclusions :**This DIVERSITY subgroup analysis study suggests favourable efficacy and comparable safety of DE versus SOC in this vulnerable population aged \< 2 years, when dosed according to an age‐ and body weight‐adjusted algorithm.

**Table 1** Efficacy and safety results of paediatric patients with VTE: Comparison of patients aged from birth‐ \< 2 years versus ≥ 2 years‐ \< 18 years
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**Background :**Anticoagulant treatment of pediatric central venous catheter‐related venous thromboembolism (CVC‐VTE) has not been prospectively evaluated. In the EINSTEIN‐Jr. trial, 500 children with any VTE were randomized to rivaroxaban or standard anticoagulants.

**Aims :**Predefined analysis of the CVC‐VTE subgroup of the EINSTEIN‐Jr. population.

**Methods :**Children with CVC‐VTE, aged birth‐17 years, received open‐label rivaroxaban or standard anticoagulants (2:1 ratio) for 1 month (children \< 2 years) or 3 months (all other children). Predefined study outcomes were recurrent VTE, other clinically relevant VTE, radiographic change in thrombotic burden, and bleeding. CVC‐associated infections were recorded. Predictors for continuation of anticoagulation beyond the study period were evaluated by logistic regression analysis.

**Results :**126 children with CVC‐VTE, 50 (40%) with symptomatic VTE, received either rivaroxaban (n = 90) or standard anticoagulants (n = 36) for a median follow‐up of 31 days (IQR 29--35; 1‐month group) and 91 days (IQR 86--95; 3‐month group). Recurrent VTE or major bleeding was not observed (95% confidence interval \[CI\], 0.0--2.8%), 3 children had clinically relevant non‐major bleeding (2.4%; 95% CI, 0.7--6.5%), and 2 had clinically relevant VTE in other locations (1.6%; 95% CI, 0.3--5.4%) (table). Complete or partial vein recanalization occurred in 57 (55%) and 38 (37%) of 103 evaluable children, respectively. CVC‐associated infection occurred in 3 (4.3%) of 69 children with normalized repeat imaging and in 6 (11.3%) of 53 children with residual VTE (odds ratio \[OR\] 0.36, 95% CI: 0.85--1.50). Anticoagulation was continued beyond the study period with residual VTE on repeat imaging (OR, 28.8; *P* = 0.0004) in children \< 2 years, continued CVC use (OR 6.8; *P* = 0.002), and potentially with symptomatic initial CVC‐VTE (OR 2.6; *P* = 0.057).

**Conclusions :**In children with CVC‐VTE, anticoagulation was efficacious and safe and resulted in a reduced clot burden in over 90% of children. Prolonged anticoagulation was associated with residual VTE on repeat imaging in children \< 2 years, continued CVC use, and symptomatic initial CVC‐VTE.

**Table 1** Clinical outcomes and radiographic change in thrombus burden by treatment groupOutcome n (%)Rivaroxaban n = 90Standard anticoagulants n = 36Absolute risk difference (95% CI)Recurrent VTE000% (−11 to 4.2%)Other clinically relevant venous thrombosis1 (1.1)1 (2.8)−1.7% (−14 to 3.6%)Major bleeding000% (−11 to 4.2%)Clinically relevant non‐major bleeding3 (3.3)03.3% (−6.4 to 9.7%)CVC related bloodstream infection7 (7.8)3 (8.3)−0.6% (−10 to 11.4%)Repeat VTE imaging -- normalised42 (47)15 (42)Repeat VTE imaging -- improved26 (29)12 (33)Repeat VTE imaging -- unchanged2 (2.2)5 (14)Repeat VTE imaging -- deteriorated1 (1.1)0
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**Background :**Antithrombin deficiency (AD) is a severe autosomal dominant thrombophilia. The natural history and genotype‐phenotype correlation of AD in children is unclear.

**Aims :**To elaborate the clinical presentation of congenital AD in children and evaluate its correlation to specific mutations in *SERPINC1*.

**Methods :**In 2017, a prospective pediatric‐database and DNA‐biorepository for congenital AD was established at Nationwide Children\'s Hospital (NCH). During the pilot/feasibility phase the database was opened at 4 tertiary‐care hospitals in Canada and the US. Approval from research‐ethics‐board was obtained at each participating hospital. Written consent/assent was obtained from guardians/subjects who met eligibility criteria. Clinical data was entered into a REDCap database. Participating centers had the option of shipping whole‐blood to NCH, where DNA extraction and *SERPINC1* sequencing were performed. Standard statistical methods were used to summarize parameters. Probability of VTE‐free survival was assessed using the Kaplan‐Meier method.

**Results :**43 participants (25 female) from 31 unique kindreds have been enrolled. Median age (range) at enrollment was 14.8 (1--21) years, median AT activity was 0.52 (0.24--0.87) IU/mL, and median AT antigen level (n = 20) was 0.41 (0.12--1.1) IU/mL. 19 (44%) participants have a history of venous thrombo‐embolism (VTE). Median age at VTE diagnosis was 12.4 (0.1--19.2) years. Thrombotic locations included leg veins (n = 13), cerebral veins (n = 5) and pulmonary embolism (n = 5). 9 (47%) VTE events were unprovoked. *SERPINC1* sequencing has been completed for 30 participants and 21 unique mutations have been identified, including 7 novel variants. Probability of 5‐year VTE‐free survival (95% CI) for carriers of missense mutations \[91.7% (81.3--100)\] is significantly higher than carriers of null mutations \[60% (33.2--100)\]; *P* \< 0.0001 (Figure 1)\]. Molecular modeling of novel variants is currently underway.

**Conclusions :**This is the first pediatric study to document a more severe thrombotic phenotype in carriers of null mutations in *SERPINC1*, when compared to carriers of missense mutations; underscoring the clinical utility of genetic‐testing.

**Figure 1** Probability of VTE free survival in children with congenital antithrombin deficiency
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**Background :**Sick neonates are at high risk of thrombosis in pediatric medicine. Besides central access devices (CAD), other maternal or neonatal risk factors have not been well studied.

**Aims :**The study aims were to report the incidence of thrombosis in a contemporary neonatal intensive care population and to identify risk factors for venous and arterial neonatal thrombosis.

**Methods :**A case‐control analysis was conducted using the Children\'s Hospitals Neonatal Database (CHND) from Jan 2010‐Dec 2016 with IRB approval. This dataset contains demographic and clinical data of 118,952 neonates admitted to 31 NICUs in the United States. Cases were neonates with a venous or arterial thrombosis during their NICU stay. Four matched controls per case were randomly selected based on gestational age, presence or absence of a CAD, hospital and admission year. Thrombosis incidence was calculated and a multivariable logistic regression analysis was performed to identify risk factors.

**Results :**The incidence of neonatal thrombosis was 15.5 per 1,000 NICU admissions (11.5 and 8.8 respectively, for venous and arterial thrombosis). For the risk factor analysis, 1022 venous and 362 arterial thrombosis cases were identified. In a multivariable logistic regression model (Table 1), venous thrombosis was significantly associated with blood stream infection (AOR = 2.07; 95% CI = 1.72, 2.49), maternal diabetes (AOR = 1.63; 95% CI = 1.30, 2.04), gastrointestinal surgery (AOR = 1.35; 95% CI = 1.17, 1.57), mechanical ventilation \> 2 days (AOR = 1.27; 95% CI = 1.10, 1.46) and thrombocytopenia (AOR = 2.43; 95% CI = 2.01, 2.93). Arterial thrombosis was significantly associated with maternal hypertension (AOR = 1.62; 95% CI = 1.22, 2.16), mechanical ventilation \> 2 days (AOR = 1.53; 95% CI = 1.20, 1.94), blood stream infection (AOR = 1.43; 95% CI = 1.01, 2.00) and thrombocytopenia (AOR = 2.16; 95% CI = 1.57, 2.98).

**Conclusions :**Multiple risk factors for venous and arterial neonatal thrombosis were identified in this case control analysis. These data will help clinicians develop guidelines to prevent thrombosis and risk stratified protocols for thromboprophylaxis in the NICU that will lead to improved neonatal outcomes.

**Table 1** Multivariable logistic regression model of all neonates (N = 1326), venous (N = 1022) and arterial thrombosis (N = 362) with OR and CIVariablesAll thrombosis casesVenous thrombosisArterial thrombosisOR (95% CI)Blood Stream Infection (BSI)1.85 (1.56, 2.18)2.07 (1.72, 2.49)1.43 (1.01, 2.00)Maternal Diabetes1.46 (1.20, 1.77)1.63 (1.30, 2.04)N/AGastrointestinal (GI) surgery1.23 (1.08, 1.41)1.35 (1.17, 1.57)N/AMechanical Ventilation1.32 (1.17, 1.50)1.27 (1.10, 1.46)1.53 (1.20, 1.94)Maternal Hypertension1.19 (1.02, 1.40)1.07 (0.89, 1.28)1.62 (1.22, 2.16)Neonatal Thrombocytopenia2.38 (2.02, 2.81)2.43 (2.01, 2.93)2.16 (1.57, 2.98)Age ≥ 7 days vs. \<7 days0.69 (0.60, 0.78)0.67 (0.58, 0.78)N/ANecrotizing enterocolitis (NEC)0.82 (0.67, 1.01)0.84 (0.66, 1.05)N/A
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**Background :**Heavy menstrual bleeding (HMB) is a common presenting symptom for an inherited bleeding disorder, and menarche is often the first hemostatic challenge for a female. The optimal management of HMB in adolescents with inherited bleeding disorders requires collaboration between hematologists and gynecologists. Comprehensive women\'s bleeding clinics provide the framework to allow this collaborative multidisciplinary approach.

**Aims :**Characterize the management of adolescent girls with inherited bleeding disorders in a large comprehensive young women\'s bleeding clinic.

**Methods :**This is a retrospective cohort study. We reviewed the records of young women seen in the Children\'s Healthcare of Atlanta (CHOA) Comprehensive Women\'s Bleeding Disorder clinic from 2018 to 2019. Demographic, diagnostic, symptomatic and treatment data were collected from electronic medical report chart review. HMB was defined as bleeding lasting 7 days, flooding or changing protection more than every 2 hours.

**Results :**Thirty‐five adolescents with bleeding disorders were seen in the Women\'s Bleeding Clinic between 2018--19. Median age was 15.5 (IQR 14.2--16.9). The majority were Caucasian (57.2%) with 31.3% of Hispanic ethnicity. Median age of menarche was 11 (IQR 10--12) with median onset of HMB at 12 years (IQR 11--13). HMB commonly presented at time of menarche (69%) but a delay up to 5 years was reported. Eleven had medical comorbidities complicating bleeding and clotting risk. The most common initial menstrual reduction therapy utilized was combined oral contraceptives (COCs) at 58.8%. The majority failed their initial menstrual reduction strategy (64.7%) taking a median number of 2 additional strategies prior to achieving optimal menstrual suppression. Two subjects with severe Type 1 VWD achieved optimal suppression using VWF concentrate infusions during the week of menses after failing multiple alternative therapies.

**Table 1** Bleeding Disorder DiagnosesDiagnosisSubjects, n (%)Type 1 VWD12 (34.3)Type 2M VWD2 (5.7)Type 2B VWD2 (5.7)Low VWF10 (28.6)Factor VII Deficiency4 (11.4)Hemophilia A Carrier1 (2.9)Mild platelet defect1 (2.9)Inherited macrothrombocytopenia syndrome1 (2.9)Delta Storage Pool Deficiency2 (5.7)

**Figure 1** Therapies for HMB in Adolescents with Bleeding Disorders: Initial and Effective Therapies

**Conclusions :**For adolescents with bleeding disorders, the ideal medical strategy remains a challenge, often requiring multiple different medical therapies prior to obtaining adequate menstrual control.
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**Background :**Von Willebrand Factor (VWF) can be activated by shear force, but the underlying molecular mechanism has remained elusive. A discontinuous autoinhibitory module (AIM) composed of both flanking regions around the A1 domain of VWF can impede its binding to platelets.

**Aims :**To test if tensile force releases the AIM from A1 and if the nanobody VHH81 that comprises FDA‐approved caplacizumab could inhibit this process.

**Methods :**Single‐molecule optical tweezers were used to apply tensile force on recombinant VWF‐A1 fragments, and bio‐layer interferometry to assess binding of VWF‐A1 with platelet GPIbα. Platelet aggregometry and laminar flow chamber assays were utilized to measure VWF‐A1‐induced platelet activation/aggregation.

**Results :**A fragment containing the AIM and A1 (residues 1238--1493) exhibits a single unfolding event around 15 pN that is attributable to the unfolding of the AIM (Fig. A,B,C). The contour length is 29.9 ± 0.5 nm, consistent with ˜60 residues in the AIM. VWF constructs lacking either N‐terminal part of the AIM (1268--1493) or C‐terminal AIM (1238--1461) show significantly altered unfolding events at lower forces (Fig A,C,D). VHH81 binds to 1,238--1,493, 1,238--1,461 but not 12,68--1,493 with high affinity, and greatly increases the unfolding force of the AIM (Fig. E,F,G). Consistently, VHH81 inhibits platelet accumulation to collagen surface at 2500/s shear rate, but the inhibition greatly diminishes at 10,000/s. In comparison, DNA aptamer ARC1172 that directly blocks the GPIbα‐binding site in A1 abolishes platelet accumulation under both shear rates (Fig. H).

**Conclusions :**We provide the first direct evidence that tensile force unfolds the AIM from A1, supporting a model in which the folded AIM binds to A1 and critically masks its binding to platelets. Furthermore, VHH81 impedes VWF binding to platelets by binding to residues in the N‐AIM and increasing the mechanical stability of the AIM. Thus, it is the first shear‐reversible antagonist of the VWF‐GPIbα interaction.

**Figure 1** Depiction of VWF fragments, single‐molecule experiments, VHH81 binding to VWF and impact on platelet adhesion
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**Background :**Genotyping von Willebrand factor (VWF) gene is not yet routine clinical practice in patients with von Willebrand disease (VWD), but may improve VWD diagnosis and can be used for genetic counseling.

**Aims :**We analyzed the VWF gene in a large cohort of VWD patients, to identify novel VWF gene variations and to perform phenotype‐genotype analyses.

**Methods :**Analysis of VWF gene was performed in 391 VWD patients (VWF levels ≤ 0.30 IU/mL) from the nationwide "Willebrand in the Netherlands" (WiN) study. Genetic analysis was performed using Iontorrent and Sanger sequencing of all 52 exons including exon‐intron boundaries (±20 bp). We did MLPA to identify large deletions. VWF and FVIII levels were measured centrally.

**Results :**Variations were identified in 158/253 type 1 patients, 123/125 type 2 and 13/13 type 3 VWD patients (Table 1). Type 1 VWD patients without a VWF gene variation had slightly higher historically lowest VWF antigen compared to type 1 patients with a VWF gene variation (0.37 IU/mL ± 0.13 vs. 0.30 IU/mL ± 0.29, *P* = 0.013), and about two times higher centrally measured VWF antigen (0.55 IU/mL ± 0.20 vs. 0.29 IU/mL ± 0.19, *P* \< 0.001)). Interestingly, there was a clear distinction in pathophysiology of type 1 VWD with‐ and without VWF gene variations: an increased clearance of VWF with a high VWFpropeptide/VWF:Ag ratio was only seen in type 1 VWD patients with varations (Figure 1). In 57 patients we found novel VWF gene variations, of which several were found in unrelated patients who had a similar laboratory phenotype, confirming pathogenicity. Twenty novel variations were classified as class 5(/5) pathogenicity. For instance, several unrelated patients with a type 2A laboratory phenotype had c.3845T\>C (p.Leu1282Pro), and type 3 VWD patients with novel homozygous VWF variations.

**Conclusions :**We provide new insights in the molecular background of VWD, and illustrate important phenotypic differences between type 1 VWD patients with‐ and without a VWF gene variation.

**Figure 1** There is a clear distinction in pathophysiology of type 1 VWD patients with‐ and without a VWF gene mutation

**Table 1** Baseline characteristicsType 1 VWD (n = 253)Type 2 VWD (n = 125)Type 3 VWD (n = 13)Age, mean (std)44 (18)\*42 (19)\*31 (21)\*Female, n (%)167 (66%)76 (61%)7 (53.8%)Blood group O, n (%)170 (69%)\*67\* (54%)\*6 (46.2%)Mutation found, n (%)158 (63%)\*123 (98.4%)\*13 (100%)\*VWF:Ag0.38 \[0.25--0.54\]\*0.26 \[0.16--0.37\]\*0.00 \[0.00--0.04\]\*VWF:Ab0.47 \[0.23--0.73\]\*0.08 \[0.03--0.18\]\*0.00 \[0.00--0.00\]\*FVIII:C0.68 \[0.49--0.88\]\*0.37 \[0.25--0.51\]\*0.01 \[0.01--0.29\]\*Bleeding score9 \[6--15\]\*11 \[8--17\]\*20 \[14--25\]\*

Data are presented as median \[interquartile ranges\], unless otherwise specified.

\**P*‐value \< 0.05 comparing patients with type 1, 2 and 3 VWD.
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**Background :**In 2009, a 9‐month old infant from a consanguineous middle‐eastern family was diagnosed with infantile myelofibrosis following investigations for splenomegaly, anemia and thrombocytopenia. Despite treatment with oral steroids, he still has evidence of myelofibrosis and platelet dysfunction, but had some improvements in platelet count and splenomegaly.

**Aims :**To identify a genetic cause for the clinical features and assist with future management.

**Methods :**Platelet function, biochemistry, signaling and bone marrow biopsies were performed to investigate thrombocytopenia and myelofibrosis. Next‐generation sequencing of 343 target genes was conducted.

**Results :**On examination, hepatosplenomegaly was noted. Stained blood films showed anisocytosis, microcytosis, tear drop poikilocytosis, some target cells and elliptocytes and mild thrombocytopenia with some enlarged and ˜30% grey platelets. By western‐blotting, total P‐selectin content was normal which may suggest *in‐vivo* degranulation. Bone marrow biopsies consistently revealed increased reticulin and collagen fibrosis and the presence of clustered atypical megakaryocytes. Two new homozygous variants were detected; *MPIG6B* c.A632T, p.Y211F removes the first G6b‐B ITIM tyrosine and is predicted to disrupt downstream signaling. Platelet aggregation was markedly reduced with 2 μg/mL collagen and 1 μg/mL CRP but increased with 2 μg/mL CLEC2 antibody. After collagen/CRP stimulation, total phosphorylation was also reduced. Immunoprecipitation experiments suggest that G6b‐B Y211 may be more important than Y237 for Shp1 interaction. The second variant, *SH2B3* c.G640A, p.G214R, affects the LNK pleckstrin‐homology domain and prevents its attachment to the cytoskeleton with consequences on MPL activation pathway (TK signaling) which is always turned on leading to increased basal signaling (phospho‐Jak2) and total phosphorylation post‐TPO stimulation.

**Conclusions :**Paediatric thrombocytopenia associated with myelofibrosis is rare and biologically different to adult disease. This is the first case of a child with variants in both *MPIG6B* and *SH2B3* altering platelet signaling and causing thrombocytopenia and myelofibrosis. Severity of thrombocytopenia may be ameliorated by p‐Jak/Stat signalling. G6b‐B ITIM‐Y211 is important for Shp1 interaction and downstream signaling.
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**Background :**It has been recommended to increase the platelet count with platelet transfusions in cirrhotic patients undergoing invasive procedures when their platelet count is lower than 50 × 10^9^/L, in order to reduce the risk of major peri‐procedural bleeding. This recommendation mostly stemmed from considerations on biological plausibility by experts, rather than being based on hard experimental evidence.

**Aims :**To investigate the association between platelet count and peri‐operative bleeding in a relatively large cohort of cirrhotic patients who underwent excision of hepatocellular carcinoma without prophylactic platelet transfusions.

**Methods :**We retrospectively evaluated 996 patients who underwent surgical excision of hepatocellular carcinoma by hepatic resection or radiofrequency ablation between 1998 and 2018 (table). Patients were allocated to three different groups based on their platelet count:

Group 1: \>100 × 10^9^/L;

Group 2: 50--100 × 10^9^/L;

Group 3: \<50 × 10^9^/L.

The primary endpoint was peri‐surgical major bleeding, based on the criteria of the ISTH. Data were analyzed by relative risk regression analysis.

**Results :**The overall event rate of perioperative bleeding was 8.9%; there was no statistically significant difference among the 3 groups of patients: Group 1 = 8%; Group 2 = 10%; Group 3 = 11% (p=n.s.). By multivariate analysis, increased incidence of major bleeding was significantly associated with the following factors: low hemoglobin level (RR 0.63, CI 0.57--0.69), age \> 65 years (RR 1.67, IC 0.97--2.89) and hepatic resection versus radiofrequency ablation (RR 2.78, CI 1.86--4.16).

**Conclusions :**Peri‐operative bleeding was not influenced by platelet count in cirrhotic patients undergoing excision of hepatocellular carcinoma without prophylactic platelet transfusions, even when the platelet count was \< 50 × 10^9^/L. Our data do not support the recommendation of transfusing platelet concentrates in patients with platelet counts \< 50 × 10^9^/L in order to decrease their peri‐operative bleeding risk.
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**Background :**Immune thrombocytopenia (ITP) is a bleeding disorder caused by autoantibodies (AAbs) against platelet′s (PLT) glycoproteins. Desialylation, the loss of sialic acid from PLT glycoproteins, has been reported to contribute to the increased PLT destruction and reduced PLT formation (Haematologica PMID: 31857361).

**Aims :**To assess the impact of desialylating AAbs on the bleeding tendency/manifestations of ITP patients.

**Methods :**The desialylation ability of 100 well‐characterized ITP patients was analysed by flow cytometry. Platelet count, bleeding tendency and platelet adhesion were investigated.

**Results :**The median PLT count of the study cohort was 32 × 10^9^/L (interquartile range \[IQR\]: 7--74 × 10^9^/L). Interestingly, a lower PLT count was found in patients with desialylating ITP‐AAbs compared to patients with non‐desialylating AAbs (median and IQR: 13 × 10^9^/L IQR 5--42 × 10^9^/L vs. 46 × 10^9^/L IQR 11--81 × 10^9^/L, *P* = 0.0286). Moreover, the bleeding events were reported in 48/100 patients and the potential impact of PLT desialylation on the bleeding manifestations was investigated. Interestingly, bleeding symptoms were often observed in patients with desialylating AAbs (% patients with bleeding: desialylating vs. non‐desialylating ITP‐AAbs, 72% vs. 28%, *P* = 0.0008). Particularly, higher tendency to develop petechiae (46% vs. 19%, *P* value 0.0044) and hematoma (49% vs. 17%, *P* value 0.0009) was observed in patients with desialylating AAbs compared to non‐desialylating once. To explore the mechanism underlying this effect we analyzed the platelet function. Impaired adhesion to fibrinogen and vWF was observed in the presence of desialylating ITP‐AAbs which was significantly improved by the pretreatment with a sialidase inhibitor (% adherent PLTs/field mean±SEM desialylating ITP‐AAbs without vs. with sialidase: 36 ± 5% vs. 86 ± 56%, *P* = 0.0001 and 26 ± 2% vs. 67 ± 11%, *P* = 0.02, respectively).

**Conclusions :**Our findings demonstrate a correlation between ITP patients with desialylating AAbs and their reduced PLT count and bleeding tendency. This suggests a potential clinical relevance of PLT′s desialylation as target for diagnostic tools and therapeutic approaches in the treatment of ITP.
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**Background :**Neutrophils are the first line of defence against bacterial infection and neutrophil extracellular traps (NETs) formation is an important protective mechanism. NETs can also cause harm by promoting intravascular coagulation and multi‐organ failure (MOF) in animal models. Although increasingly considered as important therapeutic targets, there is no robust and specific measure of NETs formation to inform clinical care and enable precision medicine in intensive care unit (ICU) patients.

**Aims :**The aim of this study is to establish a novel assay for measuring NETs and assess its clinical significance.

**Methods :**Consecutive adult ICU patients (n = 341) were prospectively enrolled following written informed consent. Complementary, mice models of sepsis (caecal ligation and puncture (CLP) or intraperitoneal injection of Escherichia coli), were performed without or with anti‐NETs therapy.

**Results :**NETs were directly induced by heterologous healthy neutrophils incubated with plasma from ICU patients, but not healthy donors. We stratified ICU patients into four groups, those with absent (22.0%), mild (49.9%), moderate (14.4%) and strong (13.8%) NETs formation, respectively. Strong NETs were predominantly in sepsis patients (*P* \< 0.0001) and associated with SOFA scores. Adjusted by APACHE II, multivariate regression showed that NETs formation on ICU admission independently predicted DIC and mortality. Interleukin (IL)‐8 levels were associated with NETs formation, inhibiting IL‐8 significantly attenuated NETosis. In septic mice, NETs positive staining was predominantly in the lungs, and could be monitored by our non‐invasive NETs assay. NETs were associated with fibrin deposition within the lungs and increases in lung injury scores, along with circulating markers of liver, kidney and cardiac injury, which was inhibited by targeting IL‐8.

**Conclusions :**This NETs assay could guide clinical management and enable targeted treatment and personalised ICU medicine. IL‐8 is a major driving factor of NETs in sepsis, with anti‐IL‐8 therapy significantly reducing NETs‐induced organ damage and mortality in septic mice.
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**Background :**Neutrophil extracellular trap formation (NETosis) and the NLR family pyrin domain containing 3 (NLRP3) inflammasome assembly are associated with a similar spectrum of human disorders including thrombosis. Mainly described in macrophages, the NLRP3 inflammasome represents a multiprotein signaling platform that mediates pivotal responses of innate immunity after activation. However, products of NLRP3 inflammasome activation are also known to play a role in NETosis. Nevertheless, nothing is known about the role of NLRP3 in neutrophils or NETosis.

**Aims :**The present study examined whether the NLRP3 inflammasome is implicated in NETosis and thus contributes to a stenosis model of deep vein thrombosis.

**Methods :**The study employed confocal microscopy, time‐lapse microscopy and stenosis‐induced deep vein thrombosis.

**Results :**Neutrophil stimulation with the well‐known NLRP3 activator nigericin or ionomycin resulted in assembly of the NLRP3 inflammasome as observed by ASC speck formation. Interestingly, ASC speck formation was significantly impaired in PAD4‐deficient neutrophils, which showed diminished ASC and NLRP3 protein levels when compared to wild‐type neutrophils. Moreover, in an *in vitro* model of NETosis, genetic deficiency of NLRP3 or pharmacological inhibition with the established inhibitor MCC950 resulted in significantly decreased NET formation after induction with inflammasome activators nigericin or monosodium urate crystals (MSU), as well as with ionomycin. Time‐lapse microscopy of ionomycin‐stimulated NLRP3‐deficient neutrophils revealed a role for NLRP3 in the breakage of the nuclear envelope during NETosis, phenocopying PAD4 deficiency. Finally, a model of stenosis‐induced deep vein thrombosis in mice unraveled a prominent role of NLRP3 in the progression and expansion of venous thrombus size.

**Conclusions :**The present observations uncover the importance of NLRP3 inflammasome/speck assembly in neutrophils. We show that NLRP3 signaling is a strong contributor to NETosis and is implicated in thrombus progression in stenosis‐induced deep vein thrombosis. Thus, NLRP3 inhibitors attenuating NETosis could be beneficial to curtail NET‐mediated inflammatory and thrombotic diseases.
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**Background :**Deep vein thrombosis (DVT) is a dramatic consequence of hypercoagulability to which contributes an inflammatory condition. Thrombi formed in the lower limbs frequently embolize causing pulmonary thromboembolism. DVT results from the cooperative action of leukocytes and platelets that interact with activated endothelial cells. We have previously shown that the proline‐rich tyrosine kinase Pyk2 is a critical regulator of platelet activation and arterial thrombosis and a promoter of vascular inflammation.

**Aims :**In this study we investigated the role of Pyk2 in DVT and we analysed the function of this kinase in the crosstalk between endothelial cells, leukocytes and platelets.

**Methods :**DVT was induced in mice by inferior vena cava (IVC) partial ligation. The contribution of Pyk2 in cell activation was analysed using a specific Pyk2 pharmacological inhibitor, PF‐4594755, and confirmed in transgenic Pyk2 knock out mice (Pyk2‐KO).

**Results :**We have demonstrated that Pyk2 is required for venous thrombosis *in vivo*, as no venous thrombi were formed in a model of IVC partial ligation in Pyk2‐KO mice compared to WT littermates. Moreover, coagulation was impaired in Pyk2‐KO mice, with a significant prolongation of the extrinsic pathway. Tissue factor expression by endothelial cells and monocytes was dependent on Pyk2 activity. Pyk2 also mediated the expression of pro‐adhesive ICAM and P‐selectin on stimulated endothelial cells and supported the release of von Willebrand factor. Accordingly, rolling and adhesion of neutrophils on endothelial cells under flow condition as well as adhesion of platelets on endothelial cells through released VWF were dependent on Pyk2. Finally, we found that Pyk2 also regulated the pro‐coagulant NETs formation by neutrophils and phosphatidylserine exposure by platelets.

**Conclusions :**Altogether our results demonstrate a critical role of Pyk2 in endothelial cells, leukocytes and platelets for the development of venous thrombosis, suggesting that Pyk2 may be a promising target in the treatment of DVT.
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**Background :**Macrophage 'training' or 'memory' describes the recently discovered phenomenon in which innate immune cells undergo extensive epigenetic and metabolic alterations in response to a specific pathogen exposure that increases their responsiveness to a subsequent, non‐specific pathogenic stimuli. Dysregulated innate immune cell 'training' has been implicated in the pathophysiology of various inflammatory diseases, however, its impact on macrophage hemostatic activity is currently unknown.

**Aims :**To characterize whether induction of innate immune memory in macrophages modulates their procoagulant phenotype.

**Methods :**Murine bone marrow‐derived macrophages were exposed to heat‐killed Candida albicans or β‐glucan to induce training, washed, then left for 7 days before lipopolysaccharide (LPS) re‐stimulation. Macrophage gene expression and function were analyzed by ELISA, RT‐PCR, calibrated automated thrombinography and plasmin generation assays.

**Results :**Gene expression analysis of trained macrophages identified significant alterations in procoagulant and antifibrinolytic gene expression. In particular, tissue factor (TF) expression on trained macrophages was enhanced 15‐fold compared to naïve macrophages and 4‐fold enhanced compared to untrained macrophages stimulated with LPS. TF‐dependent thrombin generation in the presence of trained macrophages or trained macrophage supernatant was associated with significantly shortened lag‐time compared to when LPS‐stimulated untrained macrophages were present. Pre‐treatment with methyltransferase and acetyltransferase inhibitors to erase epigenetic marks associated with innate immune memory diminished trained macrophage TF expression and extended thrombin generation lag‐time to that of untrained macrophages. Moreover, trained macrophages exhibited 100‐fold enhanced plasminogen activator inhibitor‐1 (PAI‐1) expression and demonstrated increased capacity to restrict plasmin generation.

**Conclusions :**These novel data demonstrate that induction of innate immune memory in macrophages accelerates their procoagulant activity by enhanced induction of TF expression and increased release of TF‐containing extracellular vesicles. Moreover, trained macrophages also exhibit markedly increased antifibrinolytic activity. Induction of immune memory in innate immune cells therefore lowers the threshold for expression of their pro‐inflammatory, procoagulant and antifibrinolytic activities to collectively boost their haemostatic potential.
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**Background :**Inhibition of PAR1 has been shown to ameliorate TLR3‐dependent procoagulant and inflammatory responses in mouse models of viral infection, potentially via thrombin‐PAR1 signaling on innate immune cells. However, procoagulant responses to TLR3 stimulation have been shown in human endothelium but failed in human myeloid cells.

**Aims :**To characterize the role of thrombin‐PAR signaling for TLR3‐mediated responses in EC.

**Methods :** *In vivo* responses to the TLR3 agonist poly(I:C) and PAR1/2 inhibitors were analyzed by TAT‐complex in C57BL/6J mice. The genome‐wide effect of thrombin and PAR1/2 modulation of the poly(I:C) response was analyzed by transcriptional profiling of EC. PAR1/2 effects on endothelial procoagulant and cytokine responses to poly(I:C) were studied in human EA.Hy926 and HUVEC, and mouse bEND3 cells with cleavage resistant antibodies and pharmacological inhibitors. TM‐thrombin mediated PAR activation was studied using CRISPR/cas9‐mediated TM^−/−^ EC.

**Results :**Pharmacological inhibition of PAR1/2 altered the in vivo systemic TAT‐complex, indicating that PAR1/2 modifies the PCA response to poly(I:C). Transcriptional profiling in human EC revealed that a subset of the poly(I:C) response, including TF, IL8, IL6, and adhesive molecules, was augmented by PAR1/2 or thrombin co‐stimulation, indicating an overlapping target spectrum for both receptors. Thrombin, but not the ternary (TF/VIIa/Xa) complex, replicated the potentiating effect of PAR1/2 agonist peptides on the poly(I:C)‐response. PAR1/2 cleavage resistant antibodies (WEDE15/ATAP2; SAM‐II) revealed that thrombin cleaves PAR1, but not PAR2. However, both PAR1/2 inhibitors blocked thrombin‐mediated potentiation of the poly(I:C) response, indicating PAR1‐PAR2 crosstalk/heterodimer. Blocking of VCAM‐1/E‐SELE reduced monocytes adhesion on EC surface, confirming leukocytes‐EC interaction. TM‐null EC did not alter the thrombin‐mediated augmentation responses, suggesting that thrombin does not required TM to activate PAR1/2.

**Conclusions :**Our data demonstrate that a thrombin‐PAR1/2 positive feedback loop amplifies TLR3‐mediated endothelial cell procoagulant, proinflammatory, proadhesion responses to poly(I:C) which is independent of TM‐thrombin complex. Both PAR1 and PAR2 is required for thrombin‐mediated augmentation of poly(I:C)‐induced responses.
